1190002N15Rik-CKO |
NM-CKO-00008 |
1190002N15Rik |
|
1300017j02Rik-KO |
NM-KO-190231 |
1300017j02Rik |
Immune-related |
1700007K13Rik-KO |
NM-KO-202002 |
1700007K13Rik |
|
1700009J07Rik-KO |
NM-KO-200901 |
1700009J07Rik |
|
1700045H11Rik-KO |
NM-KO-201362 |
1700045H11Rik |
|
1700074P13Rik-KO |
NM-KO-00025 |
1700074P13Rik |
|
1700094J05Rik-KO |
NM-KO-201363 |
1700094J05Rik |
|
1700121C10Rik-KO |
NM-KO-190450 |
1700121C10Rik |
unknown |
1810063I02Rik-KO |
NM-KO-200902 |
1810063I02Rik |
|
2010300C02Rik-KO |
NM-KO-201364 |
2010300C02Rik |
|
2310057M21Rik-KO |
NM-KO-190232 |
2310057M21Rik |
Immune-related |
2610028H24Rik-KO |
NM-KO-201365 |
2610028H24Rik |
|
2610528A11Rik-KO |
NM-KO-201366 |
2610528A11Rik |
|
4-1BB&PD1-HU |
NM-HU-200279 |
4-1BB,Pdcd1 |
|
4930405D11Rik-KO |
NM-KO-201117 |
4930405D11Rik |
|
4930483K19Rik-KO |
NM-KO-201367 |
4930483K19Rik |
|
4930554H23Rik-KO |
NM-KO-200903 |
4930554H23Rik |
|
4930556N13Rik-KO |
NM-KO-201118 |
4930556N13Rik |
|
4930578C19Rik-CKO |
NM-CKO-00003 |
4930578C19Rik |
|
5330417C22Rik-KO |
NM-KO-201368 |
5330417C22Rik |
|
9430015G10Rik-KO |
NM-KO-191133 |
9430015G10Rik |
Immune system, nervous system, pain |
9930012K11Rik-CKO |
NM-CKO-205218 |
9930012K11Rik |
|
A1bg-KO |
NM-KO-200806 |
A1bg |
|
A2m-KO |
NM-KO-190549 |
A2m |
Beta-amyloid metabolism related;Alzheimer's disease research related |
A2ml1-KO |
NM-KO-205474 |
A2ml1 |
secreted protein |
A4galt-KO |
NM-KO-200001 |
A4galt |
Therapeutic antibody target |
A4gnt-KO |
NM-KO-201369 |
A4gnt |
|
Aadacl2-KO |
NM-KO-205618 |
Aadacl2 |
secreted protein |
Aak1-KO |
NM-KO-200002 |
Aak1 |
Therapeutic antibody target |
Aamp-KO |
NM-KO-200807 |
Aamp |
|
Aars2-KO |
NM-KO-201370 |
Aars2 |
|
Abca1-CKO |
NM-CKO-210082 |
Abca1 |
|
Abca1-KO |
NM-KO-200628 |
Abca1 |
Studies on lipoprotein metabolism and the regulation of peroxisome proliferator activated receptor alpha (PPARalpha) on lipid metabolism |
Abca12-KO |
NM-KO-201234 |
Abca12 |
|
Abca7-KO |
NM-KO-210084 |
Abca7 |
|
Abcb11-KO |
NM-KO-18010 |
Abcb11 |
|
Abcb1a-KO |
NM-KO-200904 |
Abcb1a |
|
Abcb1a&Abcb1b-KO |
NM-KO-191211 |
Abcb1a,Abcb1b |
|
Abcb1-CKO |
NM-CKO-205105 |
Abcb1b |
|
Abcb4-KO |
NM-KO-200584 |
Abcb4 |
Diseases associated with ABCB4 include Cholestasis, Progressive Familial Intrahepatic, 3 and Gallbladder Disease 1. |
Abcb7-CKO |
NM-CKO-205204 |
Abcb7 |
|
Abcc1-KO |
NM-KO-18012 |
Abcc1 |
|
Abcc10-KO |
NM-KO-202003 |
Abcc10 |
|
ABCC2-HU |
NM-HU-200254 |
Abcc2 |
|
Abcc2-KO |
NM-KO-18017 |
Abcc2 |
|
Abcc3-KO |
NM-KO-200004 |
Abcc3 |
Therapeutic antibody target |
Abcc6-CKO |
NM-CKO-200075 |
Abcc6 |
Study on the relationship between NFE2L2 (NRF2) survival signal and glucose/energy metabolism induced by photodynamic therapy |
Abcc6-KO |
NM-KO-200005 |
Abcc6 |
Therapeutic antibody target |
Abcd1-CKO |
NM-CKO-205219 |
Abcd1 |
|
Abcd2-CKO |
NM-CKO-205227 |
Abcd2 |
|
Abcd2-KO |
NM-KO-201371 |
Abcd2 |
|
Abcd3-KO |
NM-KO-200905 |
Abcd3 |
|
Abce1-KO |
NM-KO-202004 |
Abce1 |
|
Abcg1-CKO |
NM-CKO-205232 |
Abcg1 |
|
Abcg1-CKO |
NM-CKO-200285 |
Abcg1 |
|
Abcg2-CKO |
NM-CKO-210034 |
Abcg2 |
|
Abcg2-KO |
NM-KO-18013 |
Abcg2 |
|
Abcg8-KO |
NM-KO-200906 |
Abcg8 |
|
Abhd11-KO |
NM-KO-201119 |
Abhd11 |
|
Abhd11os-KO |
NM-KO-201120 |
Abhd11os |
|
Abhd12-KO |
NM-KO-200907 |
Abhd12 |
|
Abhd18-KO |
NM-KO-205739 |
Abhd18 |
secreted protein |
Abi2-KO |
NM-KO-210085 |
Abi2 |
|
Abi3bp-CKO |
NM-CKO-00009 |
Abi3bp |
Cancer and stem cells research |
Abl2-CKO |
NM-CKO-205076 |
Abl2 |
|
Abo-KO |
NM-KO-205419 |
Abo |
secreted protein |
Abtb1-KO |
NM-KO-00001 |
Abtb1 |
liver injury and regeneration |
Acaca-CKO |
NM-CKO-200166 |
Acaca |
Studies on the metabolism of water-soluble vitamins and cofactors and the biosynthesis of fatty acyl-CoA |
Acadl-KO |
NM-KO-201235 |
Acadl |
|
Acadm-CKO |
NM-CKO-205230 |
Acadm |
|
Acadm-(E8-10 repeat) |
NM-KI-200239 |
Acadm |
Medium chain acyl-CoA dehydrogenase deficiency |
Acadsb-KO |
NM-KO-190233 |
Acadsb |
Immune-related |
Acadvl-KO |
NM-KO-200908 |
Acadvl |
|
Acan-(IRES-CreERT2) |
NM-KI-200143 |
Acan |
Cre recombinase tool |
Acap1-KO |
NM-KO-201372 |
Acap1 |
|
Acbd5-CKO |
NM-CKO-205235 |
Acbd5 |
|
Ace-KO |
NM-KO-190550 |
Ace |
Cardiovascular diseases;diabetes related |
ACE2-HU |
NM-HU-200218 |
Ace2 |
Corona virus related research |
Ace2-(2A-CreERT2) |
NM-KI-200187 |
Ace2 |
Cre recombinase tool |
Ace2-KO |
NM-KO-190906 |
Ace2 |
regulation of cardiovascular and renal function, as well as fertility , Cardiac contraction, colitis, cardiovascular and renal function, and fertility |
Ache-CKO |
NM-CKO-200270 |
Ache |
|
H11-(ACHE) |
NM-KI-00067 |
ACHE |
Cholinesterase related drug research |
Ackr2-KO |
NM-KO-200808 |
Ackr2 |
|
Ackr4-KO |
NM-KO-201374 |
Ackr4 |
|
Acly-CKO |
NM-CKO-200315 |
Acly |
|
Acly-CKO |
NM-CKO-200076 |
Acly |
Research on the innate immune system and fatty acyl-CoA biosynthesis |
Acot11-KO |
NM-KO-201375 |
Acot11 |
|
Acot7-CKO |
NM-CKO-00045 |
Acot7 |
Biosynthesis of unsaturated fatty acids,Fatty acid elongation,fatty acid metabolism |
Acox1-KO |
NM-KO-200909 |
Acox1 |
|
Acp1-KO |
NM-KO-201376 |
Acp1 |
|
Acp2-KO |
NM-KO-200006 |
Acp2 |
Therapeutic antibody target |
Acp5-KO |
NM-KO-201377 |
Acp5 |
|
Acp7-KO |
NM-KO-205745 |
Acp7 |
secreted protein |
Acpp-KO |
NM-KO-200910 |
Acpp |
|
Acsbg1-CKO |
NM-CKO-205224 |
Acsbg1 |
|
Acsl6-CKO |
NM-CKO-205208 |
Acsl6 |
|
Acsl6-KO |
NM-KO-201378 |
Acsl6 |
|
Acsm3-CKO |
NM-CKO-205226 |
Acsm3 |
|
Acsm3-KO |
NM-KO-200809 |
Acsm3 |
|
Acss1-CKO |
NM-CKO-205233 |
Acss1 |
|
Acta2-(CreERT2) |
NM-KI-200074 |
Acta2 |
Cre recombinase tool |
Acta2-KO |
NM-KO-190907 |
Acta2 |
Vasoconstriction, blood pressure, retinal barrier permeability, retinal cone and rod function |
Actin-(IRES-tdTomato) |
NM-KI-200032 |
Actb |
Red mice |
Actc1-CKO |
NM-CKO-205220 |
Actc1 |
|
Actn3-CKO |
NM-CKO-205239 |
Actn3 |
|
Actrt2-KO |
NM-KO-201379 |
Actrt2 |
|
Acvr1c-CKO |
NM-CKO-200340 |
Acvr1c |
|
Acvr1c-KO |
NM-KO-200701 |
Acvr1c |
|
Acvr2a-KO |
NM-KO-200007 |
Acvr2a |
Therapeutic antibody target |
Ada-KO |
NM-KO-202005 |
Ada |
|
Adal-CKO |
NM-CKO-205205 |
Adal |
|
Adam12-CKO |
NM-CKO-205231 |
Adam12 |
|
Adam15-KO |
NM-KO-200008 |
Adam15 |
Therapeutic antibody target |
Adam23-CKO |
NM-CKO-205206 |
Adam23 |
|
Adam28-KO |
NM-KO-205473 |
Adam28 |
secreted protein |
Adam33-CKO |
NM-CKO-205237 |
Adam33 |
|
Adam33-KO |
NM-KO-190735 |
Adam33 |
Asthma related |
Adam7-KO |
NM-KO-201380 |
Adam7 |
|
Adam8-KO |
NM-KO-200010 |
Adam8 |
Therapeutic antibody target |
Adam9-KO |
NM-KO-190736 |
Adam9 |
Alzheimer's Disease related |
Adamdec1-KO |
NM-KO-205578 |
Adamdec1 |
secreted protein |
Adamts1-KO |
NM-KO-200624 |
Adamts1 |
Breast cancer and Weill-Marchesani-like syndrome research |
Adamts1-CKO |
NM-CKO-200023 |
Adamts1 |
Cancer research |
Adamts10-KO |
NM-KO-205453 |
Adamts10 |
secreted protein |
Adamts13-KO |
NM-KO-200011 |
Adamts13 |
Therapeutic antibody target |
Adamts14-KO |
NM-KO-205517 |
Adamts14 |
secreted protein |
Adamts15-KO |
NM-KO-205542 |
Adamts15 |
secreted protein |
Adamts16-KO |
NM-KO-205501 |
Adamts16 |
secreted protein |
Adamts17-KO |
NM-KO-205464 |
Adamts17 |
secreted protein |
Adamts19-KO |
NM-KO-205537 |
Adamts19 |
secreted protein |
Adamts2-CKO |
NM-CKO-205236 |
Adamts2 |
|
Adamts2-KO |
NM-KO-200012 |
Adamts2 |
Therapeutic antibody target |
Adamts3-KO |
NM-KO-202006 |
Adamts3 |
|
Adamts4-KO |
NM-KO-200013 |
Adamts4 |
Therapeutic antibody target |
Adamts5-KO |
NM-KO-200014 |
Adamts5 |
Therapeutic antibody target |
Adamts7-CKO |
NM-CKO-205238 |
Adamts7 |
|
Adamts8-KO |
NM-KO-205475 |
Adamts8 |
secreted protein |
Adamtsl1-KO |
NM-KO-205454 |
Adamtsl1 |
secreted protein |
Adamtsl3-KO |
NM-KO-205543 |
Adamtsl3 |
secreted protein |
Adamtsl4-KO |
NM-KO-205502 |
Adamtsl4 |
secreted protein |
Adamtsl5-KO |
NM-KO-205423 |
Adamtsl5 |
secreted protein |
Adar-CKO |
NM-CKO-200239 |
Adar |
|
Adat2-KO |
NM-KO-200015 |
Adat2 |
Therapeutic antibody target |
Adck1-KO |
NM-KO-205518 |
Adck1 |
secreted protein |
Adcy8-CKO |
NM-CKO-205209 |
Adcy8 |
|
Adcy9-KO |
NM-KO-201381 |
Adcy9 |
|
Adcyap1r1-KO |
NM-KO-190669 |
Adcyap1r1 |
immune,nervous system |
Add1-KO |
NM-KO-201236 |
Add1 |
|
Add2-KO |
NM-KO-201382 |
Add2 |
|
Adgra1-CKO |
NM-CKO-205225 |
Adgra1 |
|
Adgra1-CKO |
NM-CKO-00100 |
Adgra1 |
cardiovascular system,nervous system |
Adgra2-CKO |
NM-CKO-00101 |
Adgra2 |
|
Adgrb1-CKO |
NM-CKO-205077 |
Adgrb1 |
|
Adgrd1-KO |
NM-KO-190234 |
Adgrd1 |
Immune-related |
Adgrd1-CKO |
NM-CKO-00097 |
Adgrd1 |
|
Adgre1-KO |
NM-KO-200016 |
Adgre1 |
Therapeutic antibody target |
Adgre1-(2A-CreERT2) |
NM-KI-190025 |
Adgre1 |
Cre recombinase tool |
Adgre5-KO |
NM-KO-201383 |
Adgre5 |
|
Adgrf1-KO |
NM-KO-00059 |
Adgrf1 |
|
Adgrf4-KO |
NM-KO-00055 |
Adgrf4 |
|
Adgrf5-CKO |
NM-CKO-00095 |
Adgrf5 |
cardiovascular system,homeostasis/metabolism,aging |
Adgrg2-KO |
NM-KO-200017 |
Adgrg2 |
Therapeutic antibody target |
Adgrg3-KO |
NM-KO-00054 |
Adgrg3 |
|
Adgrg6-CKO |
NM-CKO-00096 |
Adgrg6 |
|
Adgrg7-KO |
NM-KO-00056 |
Adgrg7 |
Digestive system related. |
Adh5-CKO |
NM-CKO-205234 |
Adh5 |
|
Adh7-KO |
NM-KO-201121 |
Adh7 |
|
Adipoq-KO |
NM-KO-190438 |
Adipoq |
lipid metabolism |
Adipor1-KO |
NM-KO-190666 |
Adipor1 |
obesity,diabetes |
Adipor2-KO |
NM-KO-190667 |
Adipor2 |
obesity,diabetes |
Adk-KO |
NM-KO-201237 |
Adk |
|
Adm2-KO |
NM-KO-205612 |
Adm2 |
secreted protein |
Ado-KO |
NM-KO-190236 |
Ado |
Immune-related |
Adora1-CKO |
NM-CKO-210053 |
Adora1 |
|
Adora2a-CKO |
NM-CKO-210054 |
Adora2a |
|
Adora2a-KO |
NM-KO-200018 |
Adora2a |
Therapeutic antibody target |
Adora2b-CKO |
NM-CKO-210055 |
Adora2b |
|
Adora2b-KO |
NM-KO-191066 |
Adora2b |
Immune system, inflammation |
Adora3-CKO |
NM-CKO-210056 |
Adora3 |
|
Adpgk-KO |
NM-KO-205451 |
Adpgk |
secreted protein |
Adprh-KO |
NM-KO-201384 |
Adprh |
|
Adra1a-KO |
NM-KO-190737 |
Adra1a |
Diabetes related |
Adra1d-KO |
NM-KO-190908 |
Adra1d |
Nervous system, behavior, neuronal growth and cerebellar development, neurological and mental disorders |
Adra2a-KO |
NM-KO-191174 |
Adra2a |
member of the G protein-coupled receptor superfamily. |
Adra2b-CKO |
NM-CKO-205065 |
Adra2b |
|
Adra2b-KO |
NM-KO-190635 |
Adra2b |
nervous system |
Adrb2-KO |
NM-KO-190738 |
Adrb2 |
Asthma related |
Adrb3-KO |
NM-KO-190739 |
Adrb3 |
Diabetes related |
Adtrp-KO |
NM-KO-200019 |
Adtrp |
Therapeutic antibody target |
Afap1-CKO |
NM-CKO-205207 |
Afap1 |
|
Afap1l2-KO |
NM-KO-201385 |
Afap1l2 |
|
Aff1-CKO |
NM-CKO-205078 |
Aff1 |
|
Aff2-CKO |
NM-CKO-205223 |
Aff2 |
|
Aff3-CKO |
NM-CKO-205079 |
Aff3 |
|
Afm-KO |
NM-KO-200810 |
Afm |
|
Afp-KO |
NM-KO-200020 |
Afp |
Therapeutic antibody target |
Afp-CreERT2 |
NM-TG-00009 |
Afp-CreERT2 |
Cre recombinase tool of liver |
Aga-KO |
NM-KO-201100 |
Aga |
|
Ager-KO |
NM-KO-200021 |
Ager |
Therapeutic antibody target |
Agfg1-KO |
NM-KO-200911 |
Agfg1 |
|
Agk-CKO |
NM-CKO-00026 |
Agk |
|
Agpat2-KO |
NM-KO-201122 |
Agpat2 |
|
Agr3-KO |
NM-KO-190237 |
Agr3 |
Immune-related |
Agrp-(IRES-iCre) |
NM-KI-200163 |
Agrp |
Cre recombinase tool |
Agrp-KO |
NM-KO-190636 |
Agrp |
late on-set obesity |
Agrt1a-KO |
NM-KO-00041 |
Agrt1a |
cardiovascular system,nervous system |
Agt-KO |
NM-KO-190740 |
Agt |
This gene is associated with susceptibility to essential hypertension, non-familial structural atrial fibrillation, and inflammatory bowel disease. |
Agtr1a-KO |
NM-KO-190909 |
Agtr1a |
Renal morphology and function, xenobiotic response, hyperreninemia, drinking behavior, angiotensin II-related vascular and hemodynamic responses |
Agtr1b-KO |
NM-KO-190910 |
Agtr1b |
Agtr1b/Agtr1a double gene function, blood pressure and kidney |
Agtr2-KO |
NM-KO-190911 |
Agtr2 |
Angiotensin II response, pancreatitis, myocardial infarction; cardiovascular morphology and physiology, kidney and urine morphology and physiology; glucose and fat metabolism and balance; X-linked cognitive impairment |
Ahcy-KO |
NM-KO-190238 |
Ahcy |
Immune-related |
Ahi1-CKO |
NM-CKO-00053 |
Ahi1 |
|
Ahnak-KO |
NM-KO-190239 |
Ahnak |
Immune-related |
AHR-HU |
NM-HU-200252 |
Ahr |
|
Ahr-CKO |
NM-CKO-200060 |
Ahr |
Research on DAG and IP3 signal transduction and the development and heterogeneity of ILC family |
Ahr-KO |
NM-KO-18008 |
Ahr |
|
AI467606-KO |
NM-KO-200022 |
AI467606 |
Therapeutic antibody target |
Aicda-(Cre) |
NM-KI-200160 |
Aicda |
Cre recombinase tool |
Aicda-CKO |
NM-CKO-200043 |
Aicda |
Cancer research |
Aif1l-KO |
NM-KO-201386 |
Aif1l |
|
Aifm2-KO |
NM-KO-200811 |
Aifm2 |
|
Aim2-KO |
NM-KO-202007 |
Aim2 |
|
Aimp1-CKO |
NM-CKO-00064 |
Aimp1 |
immune system,hematopoietic system |
Aipl1-KO |
NM-KO-200912 |
Aipl1 |
|
Aire-CKO |
NM-CKO-200061 |
Aire |
Primary immunodeficiency and ubiquitin-mediated proteolysis related research |
Ajuba-KO |
NM-KO-190912 |
Ajuba |
Cancer, breast cancer, glioma |
Akap1-CKO |
NM-CKO-200329 |
Akap1 |
|
Akap12-KO |
NM-KO-200609 |
Akap12 |
Cancer research |
Akap13-KO |
NM-KO-202008 |
Akap13 |
|
Akr1b10-KO |
NM-KO-205414 |
Akr1b10 |
secreted protein |
Akt1-KO |
NM-KO-190741 |
Akt1 |
Pro-Inflammatory, Anti-Apoptotic and Stress Responses related. |
Akt1s1-KO |
NM-KO-191102 |
Akt1s1 |
Ischemic brain injury; tumor |
Akt2-KO |
NM-KO-190742 |
Akt2 |
Signal Transduction related |
Akt3-KO |
NM-KO-191091 |
Akt3 |
Cell proliferation,differentiation,apoptosis,tumorigenesis,glycogen synthesis and glucose uptake; nervous system,brain development,epilepsy |
Aktip-KO |
NM-KO-200812 |
Aktip |
|
ALB&FCRN-HU |
NM-HU-200278 |
Alb,Fcgrt |
|
H11-(ALB promoter-human ALB-IRES-Luciferase-polyA) |
NM-KI-200322 |
Alb |
|
Alb-(IRES-iCre) |
NM-KI-200075 |
Alb |
Cre recombinase tool,Liver |
Alb-(DreERT2) |
NM-KI-200076 |
Alb |
Dre recombinase tool |
ALB-HU |
NM-HU-200003 |
Alb |
Drug screening |
Alb-KO |
NM-KO-200023 |
Alb |
Therapeutic antibody target |
Alb-(CreERT2) |
NM-KI-00002 |
Alb |
cre-mediated recombination system |
Alcam-KO |
NM-KO-200787 |
Alcam |
|
Alcam-KO |
NM-KO-200024 |
Alcam |
Therapeutic antibody target |
Aldh3a1-KO |
NM-KO-201387 |
Aldh3a1 |
|
Aldh3a2-KO |
NM-KO-190743 |
Aldh3a2 |
Nervous System Differentiation & Development related |
Aldh5a1-KO |
NM-KO-201238 |
Aldh5a1 |
|
Aldob-KO |
NM-KO-200602 |
Aldob |
Hereditary Fructose Intolerance research |
Aldoc-KO |
NM-KO-191089 |
Aldoc |
Glycolysis enzyme, nervous system, schizophrenia |
Alk-KO |
NM-KO-200025 |
Alk |
Therapeutic antibody target |
Alkal1-KO |
NM-KO-205747 |
Alkal1 |
secreted protein |
Alkal2-KO |
NM-KO-205748 |
Alkal2 |
secreted protein |
Alkbh3-KO |
NM-KO-190240 |
Alkbh3 |
Immune-related |
Alkbh5-KO |
NM-KO-190448 |
Alkbh5 |
mRNA methylation |
R26-(CAG-LSL-ALKBH5-3xFLAG-IRES-EGFP) |
NM-KI-190054 |
Alkbh5 |
mRNA methylation |
Alkbh5-CKO |
NM-CKO-190004 |
Alkbh5 |
Epigenetic |
Alox15-KO |
NM-KO-205055 |
Alox15 |
|
Alox15-CKO |
NM-CKO-200077 |
Alox15 |
Studies on the biosynthesis and metabolism of HETE and HPETE and IL4-mediated signaling pathways |
Alox5ap-KO |
NM-KO-201388 |
Alox5ap |
|
Alpl-KO |
NM-KO-18058 |
Alpl |
|
Amacr-KO |
NM-KO-201239 |
Amacr |
|
Ambra1-CKO |
NM-CKO-200059 |
Ambra1 |
Autophagy,cancer research |
Amelx-KO |
NM-KO-200913 |
Amelx |
|
Amfr-KO |
NM-KO-200813 |
Amfr |
|
Amh-KO |
NM-KO-200026 |
Amh |
Therapeutic antibody target |
Amhr2-(IRES-2A-CreERT2) |
NM-KI-204995 |
Amhr2 |
|
Amhr2-KO |
NM-KO-200027 |
Amhr2 |
Therapeutic antibody target |
Amotl1-KO |
NM-KO-190913 |
Amotl1 |
Peripheral permeability and maintenance of cell polarity, angiomotin-related, |
Amotl2-KO |
NM-KO-190914 |
Amotl2 |
Angiotensin-related, endothelial cell function, embryonic aortic restriction |
Ampd1-KO |
NM-KO-201389 |
Ampd1 |
|
Ampd3-KO |
NM-KO-201390 |
Ampd3 |
|
Amz2-KO |
NM-KO-201391 |
Amz2 |
|
Ang-KO |
NM-KO-201392 |
Ang |
|
Angel2-KO |
NM-KO-190744 |
Angel2 |
Inflammatory Response, aging related. |
ANGPT2-HU |
NM-HU-200247 |
Angpt2 |
|
Angpt2-KO |
NM-KO-202009 |
Angpt2 |
|
Angpt4-KO |
NM-KO-205463 |
Angpt4 |
secreted protein |
Angptl2-KO |
NM-KO-201393 |
Angptl2 |
|
ANGPTL3-HU |
NM-HU-200113 |
Angptl3 |
Cardiovascular research; drug screening |
Angptl3-KO |
NM-KO-200028 |
Angptl3 |
Therapeutic antibody target |
Angptl4-KO |
NM-KO-191067 |
Angptl4 |
Metabolic system, glucose homeostasis, lipid metabolism; tumor |
Angptl6-KO |
NM-KO-201240 |
Angptl6 |
|
Angptl7-KO |
NM-KO-205479 |
Angptl7 |
secreted protein |
Angptl8-CKO |
NM-CKO-210065 |
Angptl8 |
|
Angptl8-KO |
NM-KO-190241 |
Angptl8 |
Immune-related |
Ank2-KO |
NM-KO-201241 |
Ank2 |
|
Ankfn1-KO |
NM-KO-201123 |
Ankfn1 |
|
Ankrd2-KO |
NM-KO-201394 |
Ankrd2 |
|
Ankrd27-KO |
NM-KO-201395 |
Ankrd27 |
|
Ankrd37-KO |
NM-KO-191087 |
Ankrd37 |
Hypoxia-induced HIF-1 target gene |
Ankrd40-KO |
NM-KO-201124 |
Ankrd40 |
|
Anks1-KO |
NM-KO-201396 |
Anks1 |
|
Anp32b-CKO |
NM-CKO-00043 |
Anp32b |
|
Anpep-KO |
NM-KO-200029 |
Anpep |
Therapeutic antibody target |
Antxr1-KO |
NM-KO-200030 |
Antxr1 |
Therapeutic antibody target |
Antxr2-KO |
NM-KO-202010 |
Antxr2 |
|
Anxa1-KO |
NM-KO-200681 |
Anxa1 |
Cancer related |
Anxa10-(2A-CreERT2) |
NM-KI-200312 |
Anxa10 |
|
Anxa2-KO |
NM-KO-191068 |
Anxa2 |
Angiogenesis, thrombosis; osteoclast formation, bone resorption |
Anxa3-KO |
NM-KO-190745 |
Anxa3 |
Inflammatory Response, aging related. |
Anxa4-KO |
NM-KO-200814 |
Anxa4 |
|
Anxa5-KO |
NM-KO-190746 |
Anxa5 |
Inflammatory Response, aging related. |
Aoc1-KO |
NM-KO-205462 |
Aoc1 |
secreted protein |
Aoc3-KO |
NM-KO-200031 |
Aoc3 |
Therapeutic antibody target |
Apba1-KO |
NM-KO-190747 |
Apba1 |
Synaptic Formation and Alzheimer's Disease related |
Apba3-KO |
NM-KO-190748 |
Apba3 |
Alzheimer's Disease related |
Apbb1-KO |
NM-KO-190749 |
Apbb1 |
Beta-amyloid metabolism related;Alzheimer's disease research related |
Apbb1ip-KO |
NM-KO-200032 |
Apbb1ip |
Therapeutic antibody target |
Apbb2-KO |
NM-KO-190750 |
Apbb2 |
Beta-amyloid metabolism related;Alzheimer's disease research related;Synaptic Formation related. |
Apc-KO |
NM-KO-200612 |
Apc |
Cancer research |
Apc-CKO |
NM-CKO-200013 |
Apc |
Intestinal tumor research |
Apc-(L850X) |
NM-KI-200001 |
Apc |
Heterozygotes of this strain are highly susceptible to spontaneous intestinal adenoma formation. Homozygous mice are not viable. |
Apcdd1-KO |
NM-KO-200033 |
Apcdd1 |
Therapeutic antibody target |
Apcs-KO |
NM-KO-190001 |
Apcs |
Immune-related |
Apex1-KO |
NM-KO-202011 |
Apex1 |
|
Apex2-KO |
NM-KO-201397 |
Apex2 |
|
Apln-KO |
NM-KO-200034 |
Apln |
Therapeutic antibody target |
Aplnr-DreERT2 |
NM-KI-00132 |
Aplnr |
recombinase tool |
Aplp1-KO |
NM-KO-190751 |
Aplp1 |
Beta-amyloid metabolism related;Alzheimer's disease research related |
Apoa1-KO |
NM-KO-190752 |
Apoa1 |
Cholesterol Metabolism related |
Apoa2-KO |
NM-KO-200035 |
Apoa2 |
Therapeutic antibody target |
Apob-(Q1388H) |
NM-KI-00056 |
Apob |
lipid metabolism studies, cardiovascular disease research |
Apobec3-KO |
NM-KO-200697 |
Apobec3 |
Immune related |
Apoc3-KO |
NM-KO-200036 |
Apoc3 |
Therapeutic antibody target |
Apoc4-KO |
NM-KO-201398 |
Apoc4 |
|
Apoe-KO |
NM-KO-190565 |
Apoe |
Atherosclerosis,hyperlipidemia,hypercholesterolemia,cerebral infarction,AD,chronic hepatitis etc. |
APOE2-HU |
NM-HU-190013 |
Apoe |
Immune-related |
APOE4-HU |
NM-HU-190002 |
Apoe |
Cardiovascular disease |
APOE3-HU |
NM-HU-190003 |
Apoe |
Cardiovascular disease |
Apoh-KO |
NM-KO-200037 |
Apoh |
Therapeutic antibody target |
Apoo-KO |
NM-KO-205428 |
Apoo |
secreted protein |
AppNL-F-HU |
NM-HU-2000087 |
App |
Alzheimer's disease research |
AppNL-G-F-HU |
NM-HU-2000088 |
App |
Alzheimer's disease research |
App-KO |
NM-KO-190444 |
App |
neuronal differentiation/migration, synaptic regulation and Alzheimer's disease related |
Appl1-CKO |
NM-CKO-00118 |
Appl1 |
|
Appl2-CKO |
NM-CKO-00112 |
Appl2 |
|
Aprt-KO |
NM-KO-201242 |
Aprt |
|
Aqp1-KO |
NM-KO-190915 |
Aqp1 |
Aquaporin, eye movement imbalance, urine osmotic pressure |
Aqp11-KO |
NM-KO-202012 |
Aqp11 |
|
Aqp12-KO |
NM-KO-201399 |
Aqp12 |
|
Aqp3-KO |
NM-KO-200914 |
Aqp3 |
|
AQP4-HU |
NM-HU-210001 |
Aqp4 |
drug screening |
Aqp4-KO |
NM-KO-190243 |
Aqp4 |
Immune-related |
Aqp5-(2A-CreERT2) |
NM-KI-200313 |
Aqp5 |
|
Aqp5-(iCre) |
NM-KI-200062 |
Aqp5 |
Cre recombinase tool |
Aqp5-KO |
NM-KO-190244 |
Aqp5 |
Immune-related |
Ar-CKO |
NM-CKO-00110 |
Ar |
|
Arc-(CreERT2) |
NM-KI-200101 |
Arc |
Cre recombinase tool |
Areg-KO |
NM-KO-190002 |
Areg |
Immune-related |
Arfip2-KO |
NM-KO-190916 |
Arfip2 |
NF-kappaB signaling, regulates aggregation of huntingtin proteins |
Arg1-KO |
NM-KO-200629 |
Arg1 |
Innate immune system and IL4-mediated signal transduction events related research |
Arg1-CKO |
NM-CKO-200062 |
Arg1 |
Innate immune system and IL4-mediated signal transduction events related research |
Arg2-KO |
NM-KO-190917 |
Arg2 |
Nitric oxide and polyamine metabolism |
Arhgap1-KO |
NM-KO-202013 |
Arhgap1 |
|
Arhgap15-KO |
NM-KO-201400 |
Arhgap15 |
|
Arhgap17-KO |
NM-KO-201401 |
Arhgap17 |
|
Arhgap32-KO |
NM-KO-200915 |
Arhgap32 |
|
Arhgdia-KO |
NM-KO-201243 |
Arhgdia |
|
Arhgdib-KO |
NM-KO-201402 |
Arhgdib |
|
Arhgef1-KO |
NM-KO-201403 |
Arhgef1 |
|
Arhgef10-CKO |
NM-CKO-205080 |
Arhgef10 |
|
Arhgef10l-CKO |
NM-CKO-205081 |
Arhgef10l |
|
Arhgef16-KO |
NM-KO-201404 |
Arhgef16 |
|
Arhgef19-CKO |
NM-CKO-210017 |
Arhgef19 |
|
Arhgef5-KO |
NM-KO-200038 |
Arhgef5 |
Therapeutic antibody target |
Arhgef6-KO |
NM-KO-201405 |
Arhgef6 |
|
Arid1a-CKO |
NM-CKO-200078 |
Arid1a |
Respiratory electron transport, ATP synthesis produced by chemical permeation coupling, and heat produced by uncoupling proteins |
Arid1b-CKO |
NM-CKO-205082 |
Arid1b |
|
Arid5a-KO |
NM-KO-201406 |
Arid5a |
|
Arid5b-KO |
NM-KO-202014 |
Arid5b |
|
Arih1-KO |
NM-KO-190245 |
arih1 |
Immune-related |
Arl6ip6-KO |
NM-KO-190753 |
Arl6ip6 |
Proteostasis,aging related. |
Arntl-KO |
NM-KO-205015 |
Arntl |
|
Arntl-CKO |
NM-CKO-200063 |
Arntl |
Studies on the regulation of lipid metabolism by peroxisome proliferator-activated receptor alpha (PPARalpha) and circadian rhythm-related genes |
Arsa-KO |
NM-KO-200916 |
Arsa |
|
Arsb-KO |
NM-KO-200917 |
Arsb |
|
Arsi-KO |
NM-KO-205576 |
Arsi |
secreted protein |
Arsj-KO |
NM-KO-205598 |
Arsj |
secreted protein |
Arsk-KO |
NM-KO-205539 |
Arsk |
secreted protein |
Art1-KO |
NM-KO-201407 |
Art1 |
|
Art5-KO |
NM-KO-205540 |
Art5 |
secreted protein |
Artn-KO |
NM-KO-200039 |
Artn |
Therapeutic antibody target |
Asap3-CKO |
NM-CKO-00038 |
Asap3 |
|
Asb1-KO |
NM-KO-201408 |
Asb1 |
|
Asb4-KO |
NM-KO-200918 |
Asb4 |
|
Ascl1-CKO |
NM-CKO-200283 |
Ascl1 |
|
Ascl1-(CreERT2) |
NM-KI-200207 |
Ascl1 |
Cre tool mice |
Ascl2-CKO |
NM-CKO-200235 |
Ascl2 |
Nervous system |
Ascl3-CKO |
NM-CKO-205106 |
Ascl3 |
|
Asgr1-KO |
NM-KO-190246 |
Asgr1 |
Immune-related |
Asgr2-KO |
NM-KO-201409 |
Asgr2 |
|
Asic1-KO |
NM-KO-200040 |
Asic1 |
Therapeutic antibody target |
Aspa-KO |
NM-KO-191129 |
Aspa |
NAA scavenger,Canavan disease,nervous system,auditory |
Aspg-CKO |
NM-CKO-200260 |
Aspg |
|
Asph-KO |
NM-KO-200041 |
Asph |
Therapeutic antibody target |
Asphd1-KO |
NM-KO-201125 |
Asphd1 |
|
Aspn-KO |
NM-KO-205476 |
Aspn |
secreted protein |
Astl-KO |
NM-KO-200042 |
Astl |
Therapeutic antibody target |
Atat1-CKO |
NM-CKO-205067 |
Atat1 |
|
Ate1-CKO |
NM-CKO-200079 |
Ate1 |
Research on Arginyltransferase |
Atf4-KO |
NM-KO-200650 |
Atf4 |
Research on NGF pathway and Sertoli-Sertoli cell connection dynamics |
Atf6-CKO |
NM-CKO-200080 |
Atf6 |
Research on signal transduction mediated by p38-alpha and p38-beta and Sertoli-Sertoli cell connection dynamics |
Atf7ip-CKO |
NM-CKO-205083 |
Atf7ip |
|
Atg5-KO |
NM-KO-18004 |
Atg5 |
|
Atg5-CKO |
NM-CKO-00131 |
Atg5 |
Autophagy, Atg5 function study |
Atg9a-KO |
NM-KO-202015 |
Atg9a |
|
Atl2-KO |
NM-KO-201410 |
Atl2 |
|
Atm-CKO |
NM-CKO-200047 |
Atm |
Cancer research |
Atp10a-KO |
NM-KO-201126 |
Atp10a |
|
Atp13a2-KO |
NM-KO-200919 |
Atp13a2 |
|
Atp13a5-KO |
NM-KO-201411 |
Atp13a5 |
|
Atp2b2-KO |
NM-KO-190918 |
Atp2b2 |
Intracellular calcium homeostasis,hearing,deafness,cerebellar malformation,ear malformation |
Atp2b4-KO |
NM-KO-201412 |
Atp2b4 |
|
Atp4a-KO |
NM-KO-210024 |
Atp4a |
|
Atp4b-(CreERT2) |
NM-KI-200240 |
Atp4b |
Cre tool mice |
Atp5b-KO |
NM-KO-190247 |
Atp5b |
Immune-related |
Atp5l-KO |
NM-KO-201413 |
Atp5l |
|
Atp5md-KO |
NM-KO-201414 |
Atp5md |
|
Atp6v0d2-KO |
NM-KO-201415 |
Atp6v0d2 |
|
Atp6v1b2-KO |
NM-KO-201416 |
Atp6v1b2 |
|
Atp6v1e1-KO |
NM-KO-200815 |
Atp6v1e1 |
|
Atp6v1g2-KO |
NM-KO-191134 |
Atp6v1g2 |
Nervous system,synaptic vesicle acidification |
Atp7b-(H1071Q) |
NM-KI-18001 |
Atp7b |
|
Atpaf1-KO |
NM-KO-190248 |
Atpaf1 |
Immune-related |
Atpaf2-KO |
NM-KO-190249 |
Atpaf2 |
Immune-related |
Atpif1-KO |
NM-KO-200816 |
Atpif1 |
|
Atr-KO |
NM-KO-205054 |
Atr |
|
Atr-CKO |
NM-CKO-200081 |
Atr |
Research on ERK signal transduction and human cytomegalovirus infection |
Atrn-KO |
NM-KO-190646 |
Atrn |
Cardiovascular diseases |
Atrx-CKO |
NM-CKO-205084 |
Atrx |
|
Atxn2-KO |
NM-KO-190920 |
Atxn2 |
Microsatellite augmentation disease, type I diabetes, obesity and hypertension, hepatic steatosis, sports learning related research |
AU021092-CKO |
NM-CKO-00111 |
AU021092 |
|
Auh-CKO |
NM-CKO-210070 |
Auh |
|
Aurkc-KO |
NM-KO-200669 |
Aurkc |
Cancer related |
Avp-(IRES2-Cre) |
NM-KI-200142 |
Avp |
Cre recombinase tool |
Avpr1a-KO |
NM-KO-200043 |
Avpr1a |
Therapeutic antibody target |
Avpr1b-KO |
NM-KO-190922 |
Avpr1b |
Nervous system, hypothalamic-pituitary-adrenal axis, epilepsy |
AW121686-KO |
NM-KO-200785 |
AW121686 |
|
AW549877-KO |
NM-KO-201417 |
AW549877 |
|
Axin2-(DreERT2) |
NM-KI-200196 |
Axin2 |
Dre tool mice |
Axin2-(CreERT2) |
NM-KI-200109 |
Axin2 |
Cre recombinase tool |
Axl-KO |
NM-KO-200044 |
Axl |
Therapeutic antibody target |
Azgp1-KO |
NM-KO-201418 |
Azgp1 |
|
Azi2-KO |
NM-KO-201419 |
Azi2 |
|
B2m-KO(M-NSG) |
NM-NSG-002 |
B2m |
immunodeficiency,immune system,transplantation research |
B2m-KO |
NM-KO-18021 |
B2m |
immune system |
B3gnt5-KO |
NM-KO-202016 |
B3gnt5 |
|
B3gnt6-KO |
NM-KO-201420 |
B3gnt6 |
|
B4galnt1-KO |
NM-KO-200045 |
B4galnt1 |
Therapeutic antibody target |
B4galnt2-KO |
NM-KO-201421 |
B4galnt2 |
|
B4galt1-KO |
NM-KO-201128 |
B4galt1 |
|
B4gat1-KO |
NM-KO-201129 |
B4gat1 |
|
Bace2-KO |
NM-KO-190754 |
Bace2 |
Alzheimer's Disease related |
Bach1-KO |
NM-KO-202157 |
Bach1 |
|
Bad-KO |
NM-KO-190730 |
Bad |
Cell apoptosis |
Bahd1-KO |
NM-KO-201422 |
Bahd1 |
|
Bak1-KO |
NM-KO-200046 |
Bak1 |
Therapeutic antibody target |
Bambi-KO |
NM-KO-200047 |
Bambi |
Therapeutic antibody target |
Bank1-KO |
NM-KO-201423 |
Bank1 |
|
Bard1-KO |
NM-KO-201130 |
Bard1 |
|
Batf-KO |
NM-KO-201424 |
Batf |
|
Batf3-KO |
NM-KO-190447 |
Batf3 |
Immune-related, CD8 deficiency |
Baz1b-KO |
NM-KO-201244 |
Baz1b |
|
Bbc3-KO |
NM-KO-201425 |
Bbc3 |
|
Bbip1-KO |
NM-KO-201245 |
Bbip1 |
|
Bbox1-KO |
NM-KO-190923 |
Bbox1 |
Schizophrenia |
Bbs12-KO |
NM-KO-201426 |
Bbs12 |
|
Bbs2-KO |
NM-KO-200920 |
Bbs2 |
|
Bbs5-KO |
NM-KO-201427 |
Bbs5 |
|
BC028528-CKO |
NM-CKO-00012 |
BC028528 |
|
Bcar1-CKO |
NM-CKO-205217 |
Bcar1 |
|
Bcas1-KO |
NM-KO-201428 |
Bcas1 |
|
Bcat1-KO |
NM-KO-190551 |
Bcat1 |
hypervalinemia and hyperleucine-isoleucinemia related |
Bche-KO |
NM-KO-190755 |
Bche |
Beta-amyloid metabolism related;Alzheimer's disease research related |
Bckdk-CKO |
NM-CKO-200310 |
Bckdk |
|
Bcl2a1a-KO |
NM-KO-200700 |
Bcl2a1a |
|
Bcl2a1c-KO |
NM-KO-200048 |
Bcl2a1c |
Therapeutic antibody target |
Bcl2a1d-KO |
NM-KO-200666 |
Bcl2a1d |
cellular activities related |
Bcl2l11-KO |
NM-KO-201429 |
Bcl2l11 |
|
Bcl3-KO |
NM-KO-200049 |
Bcl3 |
Therapeutic antibody target |
Bcl6-KO |
NM-KO-190756 |
Bcl6 |
Allergy and Asthma related. |
Bcl6b-KO |
NM-KO-200050 |
Bcl6b |
Therapeutic antibody target |
Bcl7a-KO |
NM-KO-200051 |
Bcl7a |
Therapeutic antibody target |
Bcl7b-KO |
NM-KO-200052 |
Bcl7b |
Therapeutic antibody target |
Bcl7c-KO |
NM-KO-200053 |
Bcl7c |
Therapeutic antibody target |
Bcl9-KO |
NM-KO-200054 |
Bcl9 |
Therapeutic antibody target |
Bcl9l-KO |
NM-KO-200055 |
Bcl9l |
Therapeutic antibody target |
Bco2-KO |
NM-KO-201430 |
Bco2 |
|
Bcorl1-CKO |
NM-CKO-205085 |
Bcorl1 |
|
Bcr-KO |
NM-KO-190629 |
Bcr |
leukemia |
Bdkrb1-KO |
NM-KO-190924 |
Bdkrb1 |
Pain, inflammatory response |
Bdkrb2-KO |
NM-KO-190925 |
Bdkrb2 |
Vasodilation, edema, smooth muscle spasm and painful fiber irritation |
Bdnf-KO |
NM-KO-205023 |
Bdnf |
|
Bdnf-CKO |
NM-CKO-200064 |
Bdnf |
Research on ERK signaling pathway and Ras signaling pathway |
Becn1-KO |
NM-KO-18028 |
Becn1 |
autophagy, cancer research |
Becn1-CKO |
NM-CKO-18008 |
Becn1 |
cancer research,Autophagy |
Bex2-KO |
NM-KO-201431 |
Bex2 |
|
Bex6-KO |
NM-KO-201432 |
Bex6 |
|
Bglap-KO |
NM-KO-201433 |
Bglap |
|
Bhlha15-(CreERT2) |
NM-KI-200158 |
Bhlha15 |
Cre recombinase tool |
Bhlha15-(CreERT2) |
NM-KI-200080 |
Bhlha15 |
Cre recombinase tool, pancreatic acinar cells |
Bhlhb9-KO |
NM-KO-201131 |
Bhlhb9 |
|
Bhlhe40-KO |
NM-KO-191085 |
Bhlhe40 |
Immune system,autoimmune disease; control of circadian rhythm,cell differentiation |
Bicdl1-KO |
NM-KO-201434 |
Bicdl1 |
|
Bin1-KO |
NM-KO-202017 |
Bin1 |
|
Bin3-KO |
NM-KO-201435 |
Bin3 |
|
R26-(BirA) |
NM-KI-00085 |
BirA |
|
Birc2-KO |
NM-KO-190757 |
Birc2 |
Stress Responses,Apoptosis related |
Birc3-CKO |
NM-CKO-205086 |
Birc3 |
|
Birc5-CKO |
NM-CKO-200082 |
Birc5 |
Research on Protein Metabolism and Hippo Signal Transduction Pathway |
Blm-KO |
NM-KO-191081 |
Blm |
Anemia, Bloom syndrome, cancer |
Blmh-KO |
NM-KO-202018 |
Blmh |
|
Blnk-KO |
NM-KO-201436 |
Blnk |
|
Bloc1s6-KO |
NM-KO-200817 |
Bloc1s6 |
|
Bmf-KO |
NM-KO-190003 |
Bmf |
Immune-related |
Bmi1-(IRES-CreERT2) |
NM-KI-200095 |
Bmi1 |
Cre recombinase tool |
Bmp1-KO |
NM-KO-205009 |
Bmp1 |
|
Bmp1-CKO |
NM-CKO-200065 |
Bmp1 |
Research on Lipoprotein Metabolism and ERK Signal Transduction |
Bmp2-CKO |
NM-CKO-200344 |
Bmp2 |
Brachydactyly;a malformed index finger and second toe |
Bmp2-KO |
NM-KO-190528 |
Bmp2 |
Growth Factors |
Bmp3-KO |
NM-KO-190529 |
Bmp3 |
Growth Factors ,bone density,osteoblast differentiation |
Bmp6-KO |
NM-KO-190530 |
Bmp6 |
Growth Factors, iron homeostasis, fat and bone development, and ovulation. |
Bmp7-KO |
NM-KO-190531 |
Bmp7 |
Growth Factors,skeletal、 kidne developmental |
Bmpr1b-KO |
NM-KO-200056 |
Bmpr1b |
Therapeutic antibody target |
Bnip3-KO |
NM-KO-191077 |
Bnip3 |
Pro-apoptotic factor; cardiovascular system, post-ischemic ventricular remodeling; tumor |
Bnip3l-KO |
NM-KO-191078 |
Bnip3l |
Pro-apoptotic factor; blood system, red blood cells; tumor |
Bnipl-CKO |
NM-CKO-00062 |
Bnipl |
|
Bod1-KO |
NM-KO-190702 |
Bod1 |
|
Bok-KO |
NM-KO-201437 |
Bok |
|
Boll-KO |
NM-KO-190004 |
Boll |
Immune-related |
Bpi-KO |
NM-KO-205452 |
Bpi |
secreted protein |
Bpifa1-CKO |
NM-CKO-00074 |
Bpifa1 |
Epigenetic regulation of gene expression,nervous system |
Bpifa2-KO |
NM-KO-205645 |
Bpifa2 |
secreted protein |
Bpifa3-KO |
NM-KO-205665 |
Bpifa3 |
secreted protein |
Bpifb2-KO |
NM-KO-205617 |
Bpifb2 |
secreted protein |
Bpifb4-KO |
NM-KO-205646 |
Bpifb4 |
secreted protein |
Bpifb6-KO |
NM-KO-205647 |
Bpifb6 |
secreted protein |
Bpifc-KO |
NM-KO-205701 |
Bpifc |
secreted protein |
Braf-KO |
NM-KO-205008 |
Braf |
|
Braf-CKO |
NM-CKO-200073 |
Braf |
Study on the correlation between meiosis and RET signal transduction in oocytes |
Braf-(flox-V600E) |
NM-KI-190053 |
Braf |
cancer research |
Brca1-CKO |
NM-CKO-18007 |
Brca1 |
cancer research |
Brca2-CKO |
NM-CKO-200014 |
Brca2 |
Breast Cancer research |
Brd7-CKO |
NM-CKO-00034 |
Brd7 |
|
Brd9-CKO |
NM-CKO-210043 |
Brd9 |
|
Brinp1-KO |
NM-KO-201132 |
Brinp1 |
|
Brinp2-KO |
NM-KO-205702 |
Brinp2 |
secreted protein |
Brinp3-KO |
NM-KO-205719 |
Brinp3 |
secreted protein |
Brs3-KO |
NM-KO-190608 |
Brs3 |
The protein encoded by this gene is a G protein-coupled membrane receptor that binds bombesin-like peptides. This binding results in activation of a phosphatidylinositol-calcium second messenger system, with physiological effects including regulation of metabolic rate, glucose metabolism, and hypertension. |
CD147-HU |
NM-HU-2000021 |
Bsg |
Immunotherapy,drug screening |
Bsn-KO |
NM-KO-201133 |
Bsn |
|
Bsph1-KO |
NM-KO-205726 |
Bsph1 |
secreted protein |
Bst1-KO |
NM-KO-200057 |
Bst1 |
Therapeutic antibody target |
Bst2-CKO |
NM-CKO-200083 |
Bst2 |
Research on Innate Immune System and Human Cytomegalovirus Infection |
Bst2-KO |
NM-KO-200058 |
Bst2 |
Therapeutic antibody target |
Btbd10-KO |
NM-KO-00043 |
Btbd10 |
|
Btbd16-KO |
NM-KO-201438 |
Btbd16 |
|
Btbd17-KO |
NM-KO-205718 |
Btbd17 |
secreted protein |
Btd-KO |
NM-KO-200630 |
Btd |
Metabolism and Metabolism Research of Water-soluble Vitamins and Cofactors |
Btg2-KO |
NM-KO-200587 |
Btg2 |
Cancer research |
Btk-KO |
NM-KO-190005 |
Btk |
Immune-related |
BTLA-HU |
NM-HU-2000044 |
Btla |
Immunotherapy,drug screening |
BTLA-HU |
NM-HU-190040 |
Btla |
Immunotherapy,cancer research,drug screening |
Btla-KO |
NM-KO-18051 |
Btla |
|
Btn1a1-KO |
NM-KO-200059 |
Btn1a1 |
Therapeutic antibody target |
Btn2a2-KO |
NM-KO-200060 |
Btn2a2 |
Therapeutic antibody target |
Btnl1-KO |
NM-KO-200061 |
Btnl1 |
Therapeutic antibody target |
Btnl10-KO |
NM-KO-200062 |
Btnl10 |
Therapeutic antibody target |
Btnl2-KO |
NM-KO-200063 |
Btnl2 |
Therapeutic antibody target |
Btnl6-KO |
NM-KO-200065 |
Btnl6 |
Therapeutic antibody target |
Btnl9-KO |
NM-KO-190250 |
Btnl9 |
Immune-related |
Btrc-KO |
NM-KO-190695 |
Btrc |
phosphorylation-dependent ubiquitination |
Bud23-KO |
NM-KO-201134 |
Bud23 |
|
C1d-KO |
NM-KO-200818 |
C1d |
|
C1QA-HU |
NM-KI-200285 |
C1qa |
|
C1qa-CKO |
NM-CKO-200084 |
C1qa |
Complement pathways and pertussis related research |
C1qb-KO |
NM-KO-190758 |
C1qb |
Inflammatory Response, aging related. |
C1qc-KO |
NM-KO-190759 |
C1qc |
Inflammatory Response, aging related. |
C1ql1-KO |
NM-KO-200066 |
C1ql1 |
Therapeutic antibody target |
C1ql2-KO |
NM-KO-205613 |
C1ql2 |
secreted protein |
C1ql4-KO |
NM-KO-205614 |
C1ql4 |
secreted protein |
C1qtnf1-KO |
NM-KO-191210 |
C1qtnf1 |
|
R26-(LNL-C1qtnf1) |
NM-KI-190129 |
C1qtnf1 |
|
C1qtnf12-KO |
NM-KO-200067 |
C1qtnf12 |
Therapeutic antibody target |
C1qtnf2-KO |
NM-KO-200068 |
C1qtnf2 |
Therapeutic antibody target |
C1qtnf3-KO |
NM-KO-200069 |
C1qtnf3 |
Therapeutic antibody target |
C1qtnf4-KO |
NM-KO-200070 |
C1qtnf4 |
Therapeutic antibody target |
C1qtnf6-KO |
NM-KO-200071 |
C1qtnf6 |
Therapeutic antibody target |
C1qtnf7-KO |
NM-KO-200072 |
C1qtnf7 |
Therapeutic antibody target |
C1qtnf9-KO |
NM-KO-200073 |
C1qtnf9 |
Therapeutic antibody target |
C1R-HU |
NM-HU-2000075 |
C1ra |
Immunotherapy,drug screening |
C1rl-KO |
NM-KO-205519 |
C1rl |
secreted protein |
C1S-HU |
NM-HU-2000077 |
C1s1 |
Immunotherapy,drug screening |
C1s1-KO |
NM-KO-190760 |
C1s1 |
Inflammatory Response, aging related. |
C1s2-KO |
NM-KO-200074 |
C1s2 |
Therapeutic antibody target |
C2-KO |
NM-KO-190179 |
C2 |
Immune-related |
C3-HU |
NM-HU-2000079 |
C3 |
Immunotherapy,drug screening |
C3-KO |
NM-KO-191193 |
C3 |
Immune-related |
C4b-KO |
NM-KO-190761 |
C4b |
Inflammatory Response, aging related. |
C5-HU |
NM-HU-2000013 |
C5a |
Immunotherapy,cancer research,drug screening |
C5AR1-HU |
NM-HU-204989 |
C5ar1 |
|
C5ar1-CKO |
NM-CKO-200282 |
C5ar1 |
|
C5AR1&C5AR2-HU |
NM-HU-2000018 |
C5ar1,C5ar2 |
Immunotherapy,drug screening |
C5ar1-KO |
NM-KO-190180 |
C5ar1 |
Immune-related |
C5ar2-KO |
NM-KO-201439 |
C5ar2 |
|
C6-KO |
NM-KO-200075 |
C6 |
Therapeutic antibody target |
C7-KO |
NM-KO-205444 |
C7 |
secreted protein |
C8a-KO |
NM-KO-205417 |
C8a |
secreted protein |
C8g-KO |
NM-KO-205455 |
C8g |
secreted protein |
C9-KO |
NM-KO-205415 |
C9 |
secreted protein |
C9orf72-KO |
NM-KO-201246 |
C9orf72 |
|
Cab39l-KO |
NM-KO-191104 |
Cab39l |
Cancer, tumorigenesis and development |
Cabin1-KO |
NM-KO-202019 |
Cabin1 |
|
Cabp2-KO |
NM-KO-200921 |
Cabp2 |
|
Cacna1a-(E1980A) |
NM-KI-200279 |
Cacna1a |
|
Cacna1a-KO |
NM-KO-200076 |
Cacna1a |
Therapeutic antibody target |
Cacna1c-KO |
NM-KO-190926 |
Cacna1c |
Endocrine and metabolic systems, insulin secretion, glucose tolerance; nervous system, anxiety, motor coordination |
Cacna1d-CKO |
NM-CKO-205087 |
Cacna1d |
|
Cacna1i-KO |
NM-KO-201440 |
Cacna1i |
|
Cacna2d1-KO |
NM-KO-200077 |
Cacna2d1 |
Therapeutic antibody target |
Cacnb3-KO |
NM-KO-201441 |
Cacnb3 |
|
Cadm1-KO |
NM-KO-200593 |
Cadm1 |
Cancer research |
Cadm2-KO |
NM-KO-200079 |
Cadm2 |
Therapeutic antibody target |
Cadm4-KO |
NM-KO-190762 |
Cadm4 |
|
CAG-GFP |
NM-TG-00005 |
CAG-GFP |
Reporter mice,EGFP |
Calb1-(2A-EGFP-Cre) |
NM-KI-200141 |
Calb1 |
Cre recombinase tool |
Calb1-KO |
NM-KO-190927 |
Calb1 |
Nervous system, neurodegeneration and synaptic transmission, cerebellar Purkinje cells, motor coordination, aging |
Calb2-(IRES-iCre) |
NM-KI-200102 |
Calb2 |
Cre recombinase tool |
Calca-(iCre-2A) |
NM-KI-200302 |
Calca |
|
Calca-KO |
NM-KO-190928 |
Calca |
Calcitonin and calcitonin gene-related peptide-α (CGRP-α), vascular and nervous system related studies, bone mineralization |
Calcb-KO |
NM-KO-205515 |
Calcb |
secreted protein |
Calcrl-KO |
NM-KO-202020 |
Calcrl |
|
Calm1-KO |
NM-KO-190703 |
Calm1 |
The encoded protein acts as a calcium sensor and is involved in relaying signals to calcium-sensitive proteins, enzymes and ion channels. The protein-calcium complex binds target proteins to regulate several cellular processes, including smooth muscle contraction, inflammation, apoptosis and the immune response. Mutations in the human gene are associated with catecholaminergic polymorphic ventricular tachycardia and long QT syndrome 14. |
Calr3-KO |
NM-KO-200819 |
Calr3 |
|
Calr4-KO |
NM-KO-200820 |
Calr4 |
|
Calu-KO |
NM-KO-205461 |
Calu |
secreted protein |
Camk2g-KO |
NM-KO-201442 |
Camk2g |
|
Caml-KO |
NM-KO-202021 |
Caml |
|
Camp-KO |
NM-KO-201443 |
Camp |
|
Camta1-CKO |
NM-CKO-205088 |
Camta1 |
|
Cant1-KO |
NM-KO-205439 |
Cant1 |
secreted protein |
Capg-KO |
NM-KO-201444 |
Capg |
|
Capn1-KO |
NM-KO-191158 |
Capn1 |
|
Capn3-KO |
NM-KO-191159 |
Capn3 |
Mutations in this gene are associated with limb-girdle muscular dystrophies type 2A. |
Capn6-KO |
NM-KO-191160 |
Capn6 |
Calpains have been implicated in neurodegenerative processes |
Capza2-KO |
NM-KO-201445 |
Capza2 |
|
Capza3-KO |
NM-KO-200080 |
Capza3 |
Therapeutic antibody target |
Car10-KO |
NM-KO-201135 |
Car10 |
|
Car12-KO |
NM-KO-200081 |
Car12 |
Therapeutic antibody target |
Car2-KO |
NM-KO-190006 |
Car2 |
Immune-related |
Car4-(DreERT2) |
NM-KI-200193 |
Car4 |
Dre tool mice |
Car9-KO |
NM-KO-200083 |
Car9 |
Therapeutic antibody target |
Card9-KO |
NM-KO-201446 |
Card9 |
|
Carm1-CKO |
NM-CKO-190015 |
Carm1 |
Epigenetic |
Carmil2-KO |
NM-KO-200084 |
Carmil2 |
Therapeutic antibody target |
Cars-KO |
NM-KO-190253 |
Cars |
Immune-related |
Cartpt-(IRES-iCre) |
NM-KI-200094 |
Cartpt |
Cre recombinase tool |
Cartpt-KO |
NM-KO-190647 |
Cartpt |
obesity |
R26-(CAG-LSL-Cas13d-IRES-tdTomato) |
NM-KI-190063 |
Cas13d |
RNA editing,Cas13d |
R26-(Cas9) |
NM-KI-00120 |
Cas9 |
gene editing, gene modification |
R26-(CAG-LNL-Cas9-IRES-Luciferase-pA)1 |
NM-KI-18002 |
Cas9 |
Cas9,gene editing |
R26-(Cas9) |
NM-KI-00038 |
Cas9 |
gene editing, gene modification |
Casp1-KO |
NM-KO-190443 |
Casp1 |
Inflammation and cell death |
Casp2-KO |
NM-KO-201447 |
Casp2 |
|
Casp4-KO |
NM-KO-190763 |
Casp4 |
Apoptosis, Alzheimer's Disease related |
Casp4-CKO |
NM-CKO-190061 |
Casp4 |
cell pyroptosis, cell apoptosis |
Casp7-KO |
NM-KO-190929 |
Casp7 |
Apoptosis, immunity, cancer |
Casp8-KO |
NM-KO-190440 |
Casp8 |
cancer research,Apoptosis |
Casp8-CKO |
NM-CKO-190003 |
Casp8 |
cancer research,Apoptosis |
Casp9-KO |
NM-KO-202022 |
Casp9 |
|
Casr-KO |
NM-KO-205026 |
Casr |
|
Casr-CKO |
NM-CKO-200085 |
Casr |
GPCR signal transduction and proton pump inhibitor pathway, pharmacodynamics related research |
Cav1-KO |
NM-KO-190930 |
Cav1 |
Tumor suppression,vascular system,fibrosis,Berardinelli-Seip congenital lipodystrophy |
Cav3-KO |
NM-KO-200922 |
Cav3 |
|
Cavin1-KO |
NM-KO-201136 |
Cavin1 |
|
Cbfa2t2-KO |
NM-KO-200623 |
Cbfa2t2 |
Hematopoietic differentiation and acute myeloid leukemia research |
Cbfa2t2-CKO |
NM-CKO-200025 |
Cbfa2t2 |
Cancer research |
Cbfa2t3-CKO |
NM-CKO-205107 |
Cbfa2t3 |
|
Cbl-KO |
NM-KO-190007 |
Cbl |
Immune-related |
Cblb-KO |
NM-KO-190008 |
Cblb |
Immune-related |
Cblif-KO |
NM-KO-190089 |
Cblif |
Immune-related |
Cbll1-KO |
NM-KO-200768 |
Cbll1 |
|
Cbx5-KO |
NM-KO-201448 |
Cbx5 |
|
Cbx7-CKO |
NM-CKO-00114 |
Cbx7 |
|
Cby1-KO |
NM-KO-201247 |
Cby1 |
|
Ccbe1-KO |
NM-KO-202023 |
Ccbe1 |
|
Ccdc124-KO |
NM-KO-201449 |
Ccdc124 |
|
Ccdc126-KO |
NM-KO-205615 |
Ccdc126 |
secreted protein |
Ccdc151-KO |
NM-KO-201137 |
Ccdc151 |
|
Ccdc182-KO |
NM-KO-201138 |
Ccdc182 |
|
Ccdc27-KO |
NM-KO-201450 |
Ccdc27 |
|
Ccdc3-CKO |
NM-CKO-00082 |
Ccdc3 |
mortality/aging,nervous system |
Ccdc36-KO |
NM-KO-200631 |
Ccdc36 |
Research on the role of DNA double-strand break (DSB) formation in unsynaptic regions during meiotic recombination |
Ccdc42-KO |
NM-KO-190764 |
Ccdc42 |
|
Ccdc6-CKO |
NM-CKO-205128 |
Ccdc6 |
|
Ccdc70-KO |
NM-KO-205664 |
Ccdc70 |
secreted protein |
Ccdc80-KO |
NM-KO-200795 |
Ccdc80 |
|
Ccdc86-KO |
NM-KO-202024 |
Ccdc86 |
|
Ccdc92-KO |
NM-KO-201451 |
Ccdc92 |
|
Ccer2-KO |
NM-KO-205744 |
Ccer2 |
secreted protein |
Cck-(IRES-iCre) |
NM-KI-200131 |
Cck |
Cre recombinase tool |
Cckbr-KO |
NM-KO-190609 |
Cckbr |
This gene encodes a G-protein coupled receptor for gastrin and cholecystokinin (CCK), regulatory peptides of the brain and gastrointestinal tract. This protein is a type B gastrin receptor, which has a high affinity for both sulfated and nonsulfated CCK analogs and is found principally in the central nervous system and the gastrointestinal tract. A misspliced transcript variant including an intron has been observed in cells from colorectal and pancreatic tumors. |
CCL1-HU |
NM-HU-2000074 |
Ccl1 |
Immunotherapy,drug screening |
Ccl1-KO |
NM-KO-190009 |
Ccl1 |
Immune-related |
Ccl11-KO |
NM-KO-191181 |
Ccl11 |
This eosinophil-specific chemokine is thought to be involved in eosinophilic inflammatory diseases such as atopic dermatitis, allergic rhinitis, asthma and parasitic infections. |
Ccl12-KO |
NM-KO-190765 |
Ccl12 |
may contribute to tumor-associated leukocyte infiltration and to the antiviral state against HIV infection. |
Ccl17-KO |
NM-KO-190010 |
Ccl17 |
Immune-related |
Ccl19-KO |
NM-KO-190011 |
Ccl19 |
Immune-related |
Ccl2-KO |
NM-KO-205027 |
Ccl2 |
|
Ccl2-CKO |
NM-CKO-200150 |
Ccl2 |
CCR5 pathway and ERK signal transduction in macrophages |
Ccl20-KO |
NM-KO-190012 |
Ccl20 |
Immune-related |
Ccl21b-KO |
NM-KO-200679 |
Ccl21b |
|
Ccl22-KO |
NM-KO-190013 |
Ccl22 |
Immune-related |
Ccl24-KO |
NM-KO-190520 |
Ccl24 |
This gene belongs to the subfamily of small cytokine CC genes.Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. |
Ccl25-KO |
NM-KO-190015 |
Ccl25 |
Immune-related |
Ccl26-KO |
NM-KO-205516 |
Ccl26 |
secreted protein |
Ccl28-KO |
NM-KO-00166 |
Ccl28 |
|
Ccl3-KO |
NM-KO-190014 |
Ccl3 |
Immune-related |
CCL4-HU |
NM-HU-210013 |
Ccl4 |
drug screening |
Ccl4-KO |
NM-KO-190016 |
Ccl4 |
Immune-related |
CCL5-HU |
NM-HU-210014 |
Ccl5 |
drug screening |
Ccl5-KO |
NM-KO-190017 |
Ccl5 |
Immune-related |
Ccl7-KO |
NM-KO-190766 |
Ccl7 |
This gene encodes monocyte chemotactic protein 3, a secreted chemokine which attracts macrophages during inflammation and metastasis. |
Ccl8-KO |
NM-KO-190521 |
Ccl8 |
Chemokines |
Ccm2-KO |
NM-KO-201248 |
Ccm2 |
|
Ccn1-KO |
NM-KO-201249 |
Ccn1 |
|
Ccn3-KO |
NM-KO-201452 |
Ccn3 |
|
Ccn4-KO |
NM-KO-200821 |
Ccn4 |
|
Ccna2-KO |
NM-KO-200085 |
Ccna2 |
Therapeutic antibody target |
Ccnb2-KO |
NM-KO-201453 |
Ccnb2 |
|
R26-(CAG-LSL-mutant Ccnc-HA) |
NM-KI-210005 |
Ccnc |
HA tag mice |
Ccnd1-KO |
NM-KO-190767 |
Ccnd1 |
Mutations, amplification and overexpression of this gene, which alters cell cycle progression, are observed frequently in a variety of tumors and may contribute to tumorigenesis. |
Ccnd2-CKO |
NM-CKO-205108 |
Ccnd2 |
|
Ccnd3-KO |
NM-KO-190726 |
Ccnd3 |
cell cycle related |
Ccne1-KO |
NM-KO-190931 |
Ccne1 |
Cell cycle, tumor |
Ccne2-KO |
NM-KO-190932 |
Ccne2 |
Cell cycle, tumor, male fertility |
Ccng2-KO |
NM-KO-191082 |
Ccng2 |
Cell cycle; cancer, ovarian cancer, stomach cancer |
Ccny-CKO |
NM-CKO-00071 |
Ccny |
|
CCR1-HU |
NM-HU-190067 |
Ccr1 |
Immunotherapy,cancer research,drug screening |
Ccr1-KO |
NM-KO-190768 |
Ccr1 |
Knockout studies of the mouse homolog suggested the roles of this gene in host protection from inflammatory response, and susceptibility to virus and parasite. |
Ccr10-KO |
NM-KO-190019 |
Ccr10 |
Immune-related |
Ccr2-(2A-DreERT2) |
NM-KI-200023 |
Ccr2 |
Dre recombinase tool |
Ccr2-KO |
NM-KO-190018 |
Ccr2 |
Immune-related |
CCR2-HU |
NM-HU-18026 |
Ccr2 |
Immunotherapy,Cancer research,Drug screening |
Ccr3-KO |
NM-KO-190020 |
Ccr3 |
Immune-related |
Ccr4-KO |
NM-KO-191195 |
Ccr4 |
Immune-related |
CCR5-HU |
NM-HU-2000065 |
Ccr5 |
Immunotherapy,drug screening |
Ccr5-KO |
NM-KO-190021 |
Ccr5 |
Immune-related |
Ccr6-KO |
NM-KO-190022 |
Ccr6 |
Immune-related |
Ccr7-KO |
NM-KO-190023 |
Ccr7 |
Immune-related |
CCR8-HU |
NM-HU-2000048 |
Ccr8 |
Immunotherapy,drug screening |
CCR8-HU |
NM-HU-2000054 |
Ccr8 |
Immunotherapy,drug screening |
Ccr8-KO |
NM-KO-190024 |
Ccr8 |
Immune-related |
Ccr9-KO |
NM-KO-190025 |
Ccr9 |
Immune-related |
Cd101-KO |
NM-KO-201454 |
Cd101 |
|
Cd109-KO |
NM-KO-200087 |
Cd109 |
Therapeutic antibody target |
Cd14-KO |
NM-KO-190026 |
Cd14 |
Immune-related |
Cd151-KO |
NM-KO-200088 |
Cd151 |
Therapeutic antibody target |
Cd160-KO |
NM-KO-200089 |
Cd160 |
Therapeutic antibody target |
CD160-HU |
NM-HU-190057 |
Cd160 |
Immunotherapy,cancer research,drug screening |
Cd163-KO |
NM-KO-190027 |
Cd163 |
Immune-related |
Cd163l1-KO |
NM-KO-200822 |
Cd163l1 |
|
Cd164-KO |
NM-KO-205450 |
Cd164 |
secreted protein |
Cd177-KO |
NM-KO-202025 |
Cd177 |
|
CD180-HU |
NM-HU-210006 |
Cd180 |
drug screening |
Cd180-KO |
NM-KO-201455 |
Cd180 |
|
Tg(hCD19) |
NM-TG-200007 |
Cd19 |
|
Cd19-(CreERT2) |
NM-KI-200159 |
Cd19 |
Cre recombinase tool |
Cd19-(IRES-EGFP-Luci) |
NM-KI-200058 |
Cd19 |
B cell reporter |
Cd19-(iCre-IRES-tdTomato) |
NM-KI-200061 |
Cd19 |
Cre recombinase tool |
Cd19-(IRES-DTREGFP) |
NM-KI-190042 |
Cd19 |
DTR mouse |
CD19&CD3E-HU |
NM-HU-190027 |
Cd19,Cd3e |
Immune-related |
CD19-KO |
NM-KO-18001 |
Cd19 |
|
CD19-HU |
NM-HU-00110 |
Cd19 |
Immunotherapy,cancer research,drug screening |
Cd1d1-KO |
NM-KO-190769 |
Cd1d1 |
This gene encodes a divergent member of the CD1 family of transmembrane glycoproteins, which are structurally related to the major histocompatibility complex (MHC) proteins and form heterodimers with beta-2-microglobulin. |
Cd1d1&Cd1d2-KO |
NM-KO-202158 |
Cd1d1/Cd1d2 |
|
Cd1d2-KO |
NM-KO-190770 |
Cd1d2 |
This gene encodes a divergent member of the CD1 family of transmembrane glycoproteins, which are structurally related to the major histocompatibility complex (MHC) proteins and form heterodimers with beta-2-microglobulin. |
CD2-HU |
NM-HU-204986 |
Cd2 |
|
R26-(CAG-LSL-hCD2 C truncated-WPRE-polyA) |
NM-KI-200321 |
Cd2 |
|
Cd2-KO |
NM-KO-191183 |
Cd2 |
The protein encoded by this gene is a surface antigen found on all peripheral blood T-cells. The encoded protein interacts with LFA3 (CD58) on antigen presenting cells to optimize immune recognition. |
Cd2-(2A-CreERT2-WPRE-pA) |
NM-KI-18017 |
Cd2 |
Cre recombinase tool |
Cd200-KO |
NM-KO-190029 |
Cd200 |
Immune-related |
Cd200r1-KO |
NM-KO-200698 |
Cd200r1 |
Myeloid function related |
Cd200r2-KO |
NM-KO-200090 |
Cd200r2 |
Therapeutic antibody target |
Cd200r3-KO |
NM-KO-200684 |
Cd200r3 |
|
Cd200r4-KO |
NM-KO-200091 |
Cd200r4 |
Therapeutic antibody target |
Cd207-(2A-CreERT2) |
NM-KI-200021 |
Cd207 |
Cre recombinase tool |
Cd207-KO |
NM-KO-190030 |
Cd207 |
Immune-related |
Cd209a-KO |
NM-KO-190255 |
Cd209a |
Immune-related |
Cd209b-KO |
NM-KO-201456 |
Cd209b |
|
Cd209d-KO |
NM-KO-201457 |
Cd209d |
|
CD22-HU |
NM-HU-2000014 |
Cd22 |
Immunotherapy,cancer research,drug screening |
Cd22-KO |
NM-KO-200092 |
Cd22 |
Therapeutic antibody target |
Cd226-KO |
NM-KO-202026 |
Cd226 |
|
Cd244a-KO |
NM-KO-190032 |
Cd244a |
Immune-related |
Cd247-KO |
NM-KO-200093 |
Cd247 |
Therapeutic antibody target |
Cd248-KO |
NM-KO-200094 |
Cd248 |
Therapeutic antibody target |
CD24-HU |
NM-HU-2000060 |
Cd24a |
Immunotherapy,drug screening |
Cd24a-KO |
NM-KO-190031 |
Cd24a |
Immune-related |
CD27-HU |
NM-HU-2000035 |
Cd27 |
Immunotherapy,drug screening |
CD27-HU |
NM-HU-190035 |
Cd27 |
Immunotherapy,cancer research,drug screening |
Cd27-KO |
NM-KO-190033 |
Cd27 |
Immune-related |
PD-L1&CD28-HU |
NM-HU-210019 |
CD274 |
tumor research;inmmue therapy;drug screening |
PD-L1&CD27-HU |
NM-HU-200274 |
Cd274,Cd27 |
|
PD-L1&4-1BB-HU |
NM-HU-200260 |
Cd274,Tnfrsf9 |
umor research;inmmue therapy;drug screening |
Cd274-CKO |
NM-CKO-200298 |
Cd274 |
|
PD-L1&Siglec15-HU |
NM-HU-2000103 |
Cd274,Siglec15 |
Immunotherapy,cancer research,drug screening |
PD-L1&KDR-HU |
NM-HU-2000102 |
Cd274,Kdr |
Immunotherapy,cancer research,drug screening |
PD-L1-HU |
NM-HU-190039 |
Cd274 |
Immunotherapy,cancer research,drug screening |
PD-L1&SEMA4D-HU |
NM-HU-190034 |
Cd274,Sema4d |
Immunotherapy,cancer research,drug screening |
PD-L1&GITR-HU |
NM-HU-190015 |
Cd274,Tnfrsf18 |
Immune-related |
PD-L1&CD40-HU |
NM-HU-18024 |
Cd274,Cd40 |
Immunotherapy,cancer research,drug screening |
Cd274-KO |
NM-KO-18044 |
Cd274 |
inflammatory,immune system |
PD-L1&LAG3-HU |
NM-HU-00137 |
Cd274,Lag3 |
Immunotherapy,cancer research,drug screening |
PD-L1&TIGIT-HU |
NM-HU-18013 |
Cd274,Tigit |
Immunotherapy,cancer research,drug screening |
PD-L1&OX40-HU |
NM-HU-00111 |
Cd274,Tnfrsf4 |
cancer research,Immunotherapy,drug screening |
PD-L1-HU |
NM-HU-00062 |
Cd274 |
Immunotherapy,cancer research,drug screening |
PD-L1&TIM3-HU |
NM-HU-190056 |
Cd274, Havcr2 |
Immunotherapy,cancer research,drug screening |
B7H3-HU |
NM-HU-00107 |
Cd276 |
cancer research,Immunotherapy,drug screening |
Cd276-KO |
NM-KO-18039 |
Cd276 |
inflammation,autoimmunity |
CD28-HU |
NM-HU-2000036 |
Cd28 |
Immunotherapy,drug screening |
CD28-HU |
NM-HU-190011 |
Cd28 |
Immune-related |
Cd28-KO |
NM-KO-190034 |
Cd28 |
Immune-related |
Cd2ap-KO |
NM-KO-202027 |
Cd2ap |
|
Cd2bp2-KO |
NM-KO-201139 |
Cd2bp2 |
|
Cd300a-CKO |
NM-CKO-205246 |
Cd300a |
|
Cd300a-KO |
NM-KO-200095 |
Cd300a |
Therapeutic antibody target |
Cd300c2-KO |
NM-KO-201458 |
Cd300c2 |
|
Cd300e-CKO |
NM-CKO-205228 |
Cd300e |
|
Cd300lf-KO |
NM-KO-200096 |
Cd300lf |
Therapeutic antibody target |
Cd320-KO |
NM-KO-200097 |
Cd320 |
Therapeutic antibody target |
Cd33-CKO |
NM-CKO-200002 |
Cd33 |
Therapeutic antibody target |
Cd33-KO |
NM-KO-200578 |
Cd33 |
Therapeutic antibody target. Immune-related |
CD33-HU |
NM-HU-200002 |
Cd33 |
Immunotherapy,cancer research,drug screening |
Cd34-KO |
NM-KO-190035 |
Cd34 |
Immune-related |
Cd36-CKO |
NM-CKO-200086 |
Cd36 |
Scavenger receptor and the innate immune system to the binding and uptake of ligand research |
Cd36-KO |
NM-KO-190771 |
Cd36 |
this protein may have important functions as a cell adhesion molecule,Mutations in this gene cause platelet glycoprotein deficiency. |
CD36-HU |
NM-HU-00112 |
Cd36 |
Immunotherapy,cancer research,drug screening |
Cd37-KO |
NM-KO-200099 |
Cd37 |
Therapeutic antibody target |
CD38-HU |
NM-HU-190059 |
Cd38 |
Immunotherapy,cancer research,drug screening |
Cd38-KO |
NM-KO-190036 |
Cd38 |
Immune-related |
Cd3d-KO |
NM-KO-190719 |
Cd3d |
Immune related |
CD3E&3D&3G-HU |
NM-HU-2000017 |
Cd3e,3d,3g |
Immunotherapy,drug screening |
Cd3e-KO |
NM-KO-190727 |
Cd3e |
Immune related |
CD3E-HU |
NM-HU-00114 |
Cd3e |
Immunotherapy,cancer research,drug screening |
Cd3g-KO |
NM-KO-190720 |
Cd3g |
Immune related |
CD4-HU |
NM-HU-2000053 |
Cd4 |
Immunotherapy,drug screening |
Cd4-(IRES-DTREGFP) |
NM-KI-190121 |
Cd4 |
DTR mouse |
Cd4-KO |
NM-KO-190441 |
Cd4 |
immune system, immunodeficiency |
Cd4-(2A-DreERT2) |
NM-KI-190030 |
Cd4 |
Dre recombinase tool |
CD4-HU |
NM-HU-00115 |
Cd4 |
Immunotherapy,cancer research,drug screening |
CD40&CD40L-HU |
NM-HU-200268 |
Cd40,Cd40lg |
|
CD40-HU(Rag2&Il2rg-KO) |
NM-HU-2000112 |
Cd40 |
Immunotherapy,cancer research,drug screening |
CD40-HU |
NM-HU-2000047 |
Cd40 |
Immunotherapy,drug screening |
Cd40-KO |
NM-KO-190038 |
Cd40 |
Immune-related |
CD40-HU |
NM-HU-00076 |
Cd40 |
cancer research,Immunotherapy,drug screening |
CD40L-HU |
NM-HU-2000052 |
Cd40lg |
Immunotherapy,drug screening |
CD40L-HU |
NM-HU-2000033 |
Cd40lg |
Immunotherapy,drug screening |
Cd44-KO |
NM-KO-190039 |
Cd44 |
Immune-related |
R26-(SA-CD46-IRES-tdTomato) |
NM-KI-190087 |
CD46 |
Immune-related |
Cd46-KO |
NM-KO-190040 |
Cd46 |
Immune-related |
CD47-HU |
NM-HU-2000022 |
Cd47 |
Immunotherapy,drug screening |
Cd47-KO |
NM-KO-190041 |
Cd47 |
Immune-related |
CD47-HU |
NM-HU-00050 |
Cd47 |
Immunotherapy,cancer research,drug screening |
Cd48-KO |
NM-KO-190734 |
Cd48 |
Immune related |
Cd5-KO |
NM-KO-190042 |
Cd5 |
Immune-related |
CD52-HU |
NM-HU-2000058 |
Cd52 |
Immunotherapy,drug screening |
Cd52-KO |
NM-KO-200100 |
Cd52 |
Therapeutic antibody target |
Cd53-KO |
NM-KO-201459 |
Cd53 |
|
Cd55-KO |
NM-KO-200101 |
Cd55 |
Therapeutic antibody target |
Cd59a-KO |
NM-KO-200102 |
Cd59a |
Therapeutic antibody target |
Cd59b-KO |
NM-KO-200103 |
Cd59b |
Therapeutic antibody target |
Cd5l-KO |
NM-KO-191204 |
Cd5l |
Immune-related |
CD6-HU |
NM-HU-204985 |
Cd6 |
|
Cd6-KO |
NM-KO-190043 |
Cd6 |
Immune-related |
Cd63-KO |
NM-KO-190044 |
Cd63 |
Immune-related |
Cd68-(2A-Cre) |
NM-KI-200192 |
Cd68 |
Tool Mice |
Cd68-(IRES-CreERT2) |
NM-KI-200162 |
Cd68 |
Cre recombinase tool |
Cd68-(IRES-Cre) |
NM-KI-200161 |
Cd68 |
Cre recombinase tool |
Cd68-KO |
NM-KO-190045 |
Cd68 |
Immune-related |
Cd69-KO |
NM-KO-190046 |
Cd69 |
Immune-related |
Cd7-KO |
NM-KO-190047 |
Cd7 |
Immune-related |
Cd70-KO |
NM-KO-190048 |
Cd70 |
Immune-related |
Cd72-KO |
NM-KO-201460 |
Cd72 |
|
Cd74-KO |
NM-KO-200715 |
Cd74 |
The protein encoded by this gene associates with class II major histocompatibility complex (MHC) and is an important chaperone that regulates antigen presentation for immune response. |
CD74-HU |
NM-HU-2000082 |
Cd74 |
Immunotherapy,drug screening |
CD79A-HU |
NM-HU-200217 |
Cd79a |
Immune-related; tumor research; drug screening |
Cd79a-KO |
NM-KO-191179 |
Cd79a |
Immune related |
CD79B-HU |
NM-HU-2000012 |
Cd79b |
Immunotherapy,cancer research,drug screening |
Cd79b-KO |
NM-KO-200104 |
Cd79b |
Therapeutic antibody target |
Cd80-KO |
NM-KO-190184 |
Cd80 |
Immune-related |
CD80-HU |
NM-HU-00074 |
Cd80 |
cancer research,immune system |
CD81&OCLN-HU |
NM-HU-2000107 |
Cd81,Ocln |
Immunotherapy,cancer research,drug screening |
Cd81-KO |
NM-KO-190733 |
Cd81 |
Immune related |
CD81-HU |
NM-HU-190041 |
Cd81 |
Immunotherapy,cancer research,drug screening |
Cd82-KO |
NM-KO-200105 |
Cd82 |
Therapeutic antibody target |
Cd83-KO |
NM-KO-190051 |
Cd83 |
Immune-related |
Cd84-KO |
NM-KO-200106 |
Cd84 |
Therapeutic antibody target |
Cd86-KO |
NM-KO-18041 |
Cd86 |
immune system |
CD86-HU |
NM-HU-00045 |
Cd86 |
Immunotherapy,cancer research,drug screening |
CD8a-(luci-2A-tdTomato) |
NM-KI-200208 |
CD8a |
Fluorescence Tracer Mice |
Cd8a-(IRES-DTREGFP) |
NM-KI-190045 |
Cd8a |
DTR mouse |
Cd8a-KO |
NM-KO-190181 |
Cd8a |
Immune-related |
Cd8a-(V5-IRES-luci-2A-EGFP) |
NM-KI-18030 |
Cd8a |
gene tracing |
Cd8b1-KO |
NM-KO-190183 |
Cd8b1 |
Immune-related |
Cd9-KO |
NM-KO-191125 |
Cd9 |
Cancer, reproductive system, female infertility |
Cd93-KO |
NM-KO-201461 |
Cd93 |
|
Cd96-KO |
NM-KO-201462 |
Cd96 |
|
CD96-HU |
NM-HU-2000059 |
Cd96 |
Immunotherapy,drug screening |
Cd99l2-KO |
NM-KO-200665 |
Cd99l2 |
|
Cdc27-KO |
NM-KO-190933 |
Cdc27 |
Cell cycle, mitosis |
Cdc7-KO |
NM-KO-202028 |
Cdc7 |
|
Cdc73-KO |
NM-KO-210048 |
Cdc73 |
|
Cdcp1-KO |
NM-KO-200107 |
Cdcp1 |
Therapeutic antibody target |
Cdcp2-KO |
NM-KO-205692 |
Cdcp2 |
secreted protein |
Cdh1-(2A-DreERT2) |
NM-KI-190031 |
Cdh1 |
Dre recombinase tool |
Cdh1-CKO |
NM-CKO-18016 |
Cdh1 |
|
Cdh10-CKO |
NM-CKO-205109 |
Cdh10 |
|
Cdh17-KO |
NM-KO-200109 |
Cdh17 |
Therapeutic antibody target |
Cdh19-KO |
NM-KO-200657 |
Cdh19 |
Cancer related |
Cdh23-KO |
NM-KO-200823 |
Cdh23 |
|
Cdh3-KO |
NM-KO-200110 |
Cdh3 |
Therapeutic antibody target |
Cdh5-(m2rtTa) |
NM-KI-200205 |
Cdh5 |
m2rtTa tool mice |
Cdh5-(2A-CreERT2) |
NM-KI-200173 |
Cdh5 |
Cre recombinase tool |
Cdh6-(CreERT2) |
NM-KI-200140 |
Cdh6 |
Cre recombinase tool |
Cdh6-KO |
NM-KO-200111 |
Cdh6 |
Therapeutic antibody target |
Cdh8-KO |
NM-KO-190934 |
Cdh8 |
Nervous system, CNS synaptic transmission |
Cdk10-KO |
NM-KO-202029 |
Cdk10 |
|
Cdk12-CKO |
NM-CKO-190059 |
Cdk12 |
Cancer |
Cdk2-KO |
NM-KO-190052 |
Cdk2 |
Immune-related |
Cdk4-KO |
NM-KO-190614 |
Cdk4 |
The protein encoded by this gene is a member of the Ser/Thr protein kinase family.It is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression. The activity of this kinase is restricted to the G1-S phase, which is controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16(INK4a). This kinase was shown to be responsible for the phosphorylation of retinoblastoma gene product (Rb). |
Cdk5r1-KO |
NM-KO-190256 |
Cdk5r1 |
Immune-related |
Cdk5rap2-CKO |
NM-CKO-00055 |
Cdk5rap2 |
Hertwig's anemia. |
Cdk9-KO |
NM-KO-190053 |
Cdk9 |
Immune-related |
Cdkl2-KO |
NM-KO-201463 |
Cdkl2 |
|
Cdkn1a-CKO |
NM-CKO-200033 |
Cdkn1a |
Cancer research |
Cdkn1a-KO |
NM-KO-190774 |
Cdkn1a |
Mice that lack this gene have the ability to regenerate damaged or missing tissue. |
Cdkn1b-KO |
NM-KO-200622 |
Cdkn1b |
Cell cycle research; multiple endocrine neoplasia type IV (MEN4) research |
Cdkn1b-CKO |
NM-CKO-200032 |
Cdkn1b |
Cancer research |
Cdkn2a-CKO |
NM-CKO-200151 |
Cdkn2a |
Research on protein metabolism and ERK signal transduction |
Cdkn2a-CKO |
NM-CKO-200015 |
Cdkn2a |
Cancer research |
Cdkn2a-KO |
NM-KO-190633 |
Cdkn2a |
cancer |
Cdkn2a-(Luc-tdTomato-CreERT2) |
NM-KI-18039 |
Cdkn2a |
|
Cdkn2b-KO |
NM-KO-190621 |
Cdkn2b |
This gene lies adjacent to the tumor suppressor gene CDKN2A in a region that is frequently mutated and deleted in a wide variety of tumors. This gene encodes a cyclin-dependent kinase inhibitor, which forms a complex with CDK4 or CDK6, and prevents the activation of the CDK kinases, thus the encoded protein functions as a cell growth regulator that controls cell cycle G1 progression. |
Cdkn2c-CKO |
NM-CKO-205110 |
Cdkn2c |
|
Cdkn3-KO |
NM-KO-190622 |
Cdkn3 |
The protein encoded by this gene belongs to the dual specificity protein phosphatase family. It was identified as a cyclin-dependent kinase inhibitor, and has been shown to interact with, and dephosphorylate CDK2 kinase, thus prevent the activation of CDK2 kinase. This gene was reported to be deleted, mutated, or overexpressed in several kinds of cancers. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
Cdnf-KO |
NM-KO-205546 |
Cdnf |
secreted protein |
Cdx2-(IRES-FLP) |
NM-KI-200307 |
Cdx2 |
|
Cdx2-CKO |
NM-CKO-200036 |
Cdx2 |
Cancer research |
Ceacam1-KO |
NM-KO-190054 |
Ceacam1 |
Immune-related |
Ceacam2-KO |
NM-KO-200112 |
Ceacam2 |
Therapeutic antibody target |
Ceacam3-KO |
NM-KO-200824 |
Ceacam3 |
|
Ceacam5-KO |
NM-KO-200113 |
Ceacam5 |
Therapeutic antibody target |
Cebpb-CKO |
NM-CKO-200087 |
Cebpb |
Research on signal transduction mediated by p38-alpha and p38-beta and signal transduction events mediated by IL4 |
Cebpe-KO |
NM-KO-201464 |
Cebpe |
|
Cebpg-KO |
NM-KO-201465 |
Cebpg |
|
Cel-KO |
NM-KO-200825 |
Cel |
|
Cela1-KO |
NM-KO-205545 |
Cela1 |
secreted protein |
Cela1-(2A-DreERT2) |
NM-KI-190094 |
Cela1 |
Dre recombinase tool, pancreatic acinar cells |
Cela2a-KO |
NM-KO-205480 |
Cela2a |
secreted protein |
Cenpx-KO |
NM-KO-191189 |
Cenpx |
Epigenetic |
Cenpx-CKO |
NM-CKO-190056 |
Cenpx |
Epigenetic |
Cep104-KO |
NM-KO-201466 |
Cep104 |
|
Cep290-KO |
NM-KO-200923 |
Cep290 |
|
Cep76-KO |
NM-KO-201467 |
Cep76 |
|
Cept1-KO |
NM-KO-200115 |
Cept1 |
Therapeutic antibody target |
Cerk-KO |
NM-KO-201468 |
Cerk |
|
Cers2-CKO |
NM-CKO-00052 |
Cers2 |
|
Cers3-KO |
NM-KO-202030 |
Cers3 |
|
Cers6-KO |
NM-KO-201469 |
Cers6 |
|
Ces1c-CKO |
NM-CKO-200152 |
Ces1c |
Participate in research on extracellular metabolism of lung surfactant |
Ces1c-KO |
NM-KO-200579 |
Ces1c |
Drug metabolism research |
Ces4a-KO |
NM-KO-205625 |
Ces4a |
secreted protein |
Ces5a-KO |
NM-KO-205649 |
Ces5a |
secreted protein |
Cfap410-KO |
NM-KO-200924 |
Cfap410 |
|
CFB-HU |
NM-HU-2000078 |
Cfb |
Immunotherapy,drug screening |
Cfc1-KO |
NM-KO-201250 |
Cfc1 |
|
Cfd-KO |
NM-KO-200116 |
Cfd |
Therapeutic antibody target |
Cfhr1-KO |
NM-KO-190775 |
Cfhr1 |
Mutations in this gene are associated with an increased risk of atypical hemolytic-uremic syndrome. |
Cfhr2-KO |
NM-KO-200683 |
Cfhr2 |
Involved in regulation of complement |
Cfi-KO |
NM-KO-200117 |
Cfi |
Therapeutic antibody target |
Cfp-KO |
NM-KO-200118 |
Cfp |
Therapeutic antibody target |
Cga-KO |
NM-KO-200119 |
Cga |
Therapeutic antibody target |
Cgn-KO |
NM-KO-190055 |
Cgn |
Immune-related |
Cgref1-KO |
NM-KO-205581 |
Cgref1 |
secreted protein |
Cgrrf1-KO |
NM-KO-201470 |
Cgrrf1 |
|
Chadl-KO |
NM-KO-205426 |
Chadl |
secreted protein |
Chat-CKO |
NM-CKO-200153 |
Chat |
Research on neurotransmitter release cycle and sympathetic nerve pathway (preganglionic and postganglionic connection) |
Chchd1-KO |
NM-KO-201471 |
Chchd1 |
|
Chd3-CKO |
NM-CKO-00037 |
Chd3 |
|
Chd8-KO |
NM-KO-201140 |
Chd8 |
|
Chek1-KO |
NM-KO-190561 |
Chek1 |
cancer research |
Chek2-CKO |
NM-CKO-205111 |
Chek2 |
|
Chga-(CreERT2) |
NM-KI-204993 |
Chga |
|
Chgb-KO |
NM-KO-190935 |
Chgb |
Adrenal chromaffin cell function, catecholamine secretion, Parkinson's disease |
Chia1-KO |
NM-KO-190776 |
Chia1 |
The variations in this gene can lead to asthma susceptibility. |
Chid1-KO |
NM-KO-00029 |
Chid1 |
immune system,metabolism |
Chil1-KO |
NM-KO-190777 |
Chil1 |
The protein is thought to play a role in the process of inflammation and tissue remodeling. |
Chit1-KO |
NM-KO-201472 |
Chit1 |
|
Chmp4c-KO |
NM-KO-200746 |
Chmp4c |
|
Chordc1-KO |
NM-KO-201251 |
Chordc1 |
|
Chrd-KO |
NM-KO-201252 |
Chrd |
|
Chrdl1-KO |
NM-KO-200120 |
Chrdl1 |
Therapeutic antibody target |
Chrdl2-KO |
NM-KO-205427 |
Chrdl2 |
secreted protein |
Chrm1-KO |
NM-KO-191175 |
Chrm1 |
The muscarinic cholinergic receptor 1 is involved in mediation of vagally-induced bronchoconstriction and in the acid secretion of the gastrointestinal tract. |
Chrm4-KO |
NM-KO-191176 |
Chrm4 |
G protein-coupled receptors |
Chrm5-KO |
NM-KO-191177 |
Chrm5 |
G protein-coupled receptors,mouse studies link its function to adenylyl cyclase inhibition. |
Chrna2-KO |
NM-KO-200121 |
Chrna2 |
Therapeutic antibody target |
Chrna4-KO |
NM-KO-190567 |
Chrna4 |
Mutations in this gene cause nocturnal frontal lobe epilepsy type 1. |
Chrna5-KO |
NM-KO-190568 |
Chrna5 |
Defects in this gene have been linked to susceptibility to lung cancer type 2 (LNCR2). |
Chrna6-KO |
NM-KO-190569 |
Chrna6 |
Single nucleotide polymorphisms in this gene have been associated with both nicotine and alcohol dependence. |
Chrna7-CKO |
NM-CKO-200088 |
Chrna7 |
Drug Metabolism-Research on Cytochrome P450 and Transmission across Chemical Synapses |
Chrna7-Fan1-KO |
NM-KO-18062 |
Chrna7,Fan1 |
|
Chrnb1-KO |
NM-KO-190936 |
Chrnb1 |
Nervous system, slow channel congenital muscle weakness syndrome |
Chst1-KO |
NM-KO-201473 |
Chst1 |
|
Chst15-KO |
NM-KO-201474 |
Chst15 |
|
Chst2-KO |
NM-KO-201475 |
Chst2 |
|
Chst3-KO |
NM-KO-200925 |
Chst3 |
|
Chst4-KO |
NM-KO-201476 |
Chst4 |
|
Chst9-KO |
NM-KO-205547 |
Chst9 |
secreted protein |
Chsy1-KO |
NM-KO-190704 |
Chsy1 |
Involved in many biological processes including cell proliferation and morphogenesis. |
Cideb-KO |
NM-KO-201477 |
Cideb |
|
Ciita-KO |
NM-KO-191207 |
Ciita |
Immune-related |
Cilp-KO |
NM-KO-205468 |
Cilp |
secreted protein |
Cilp2-KO |
NM-KO-205580 |
Cilp2 |
secreted protein |
Cirbp-KO |
NM-KO-190257 |
Cirbp |
Immune-related |
Ciz1-KO |
NM-KO-201478 |
Ciz1 |
|
Ckap2-KO |
NM-KO-200122 |
Ckap2 |
Therapeutic antibody target |
Ckap4-CKO |
NM-CKO-200259 |
Ckap4 |
|
Ckap4-KO |
NM-KO-200123 |
Ckap4 |
Therapeutic antibody target |
Ckb-KO |
NM-KO-201479 |
Ckb |
|
Cklf-KO |
NM-KO-205523 |
Cklf |
secreted protein |
Clca1-KO |
NM-KO-201480 |
Clca1 |
|
Clca3a1-KO |
NM-KO-190778 |
Clca3a1 |
|
Clca3a2-KO |
NM-KO-190779 |
Clca3a2 |
|
Clca3b-KO |
NM-KO-190780 |
Clca3b |
|
Clcn3-KO |
NM-KO-202031 |
Clcn3 |
|
Clcn5-KO |
NM-KO-200926 |
Clcn5 |
|
Clcn6-KO |
NM-KO-200927 |
Clcn6 |
|
Clcnka-KO |
NM-KO-200928 |
Clcnka |
|
Clcnkb-KO |
NM-KO-201253 |
Clcnkb |
|
Cldn14-KO |
NM-KO-200837 |
Cldn14 |
|
Cldn16-KO |
NM-KO-200632 |
Cldn16 |
Sertoli-Sertoli cell junction dynamics and cell junction organization related research |
Cldn18-KO |
NM-KO-200124 |
Cldn18 |
Therapeutic antibody target |
Cldn2-KO |
NM-KO-200125 |
Cldn2 |
Therapeutic antibody target |
Cldn3-KO |
NM-KO-200126 |
Cldn3 |
Therapeutic antibody target |
Cldn4-(IRES-FLP) |
NM-KI-200308 |
Cldn4 |
|
Cldn6-KO |
NM-KO-200127 |
Cldn6 |
Therapeutic antibody target |
Clec10a-KO |
NM-KO-190221 |
Clec10a |
Immune-related |
Clec12a-KO |
NM-KO-190222 |
Clec12a |
Immune-related |
Clec12b-KO |
NM-KO-190223 |
Clec12b |
Immune-related |
Clec14a-KO |
NM-KO-200128 |
Clec14a |
Therapeutic antibody target |
Clec18a-CKO |
NM-CKO-00006 |
Clec18a |
|
Clec1b-KO |
NM-KO-190229 |
Clec1b |
Immune-related |
Clec2d-KO |
NM-KO-200129 |
Clec2d |
Therapeutic antibody target |
Clec3a-KO |
NM-KO-205622 |
Clec3a |
secreted protein |
Clec3b-KO |
NM-KO-00169 |
Clec3b |
|
Clec4a2-KO |
NM-KO-190214 |
Clec4a2 |
Immune-related |
Clec4a4-KO |
NM-KO-201481 |
Clec4a4 |
|
Clec4b1-KO |
NM-KO-200130 |
Clec4b1 |
Therapeutic antibody target |
Clec4b2-KO |
NM-KO-190781 |
Clec4b2 |
cell adhesion, cell-cell signalling, glycoprotein turnover, and roles in inflammation and immune response |
Clec4d-KO |
NM-KO-201482 |
Clec4d |
|
Clec4e-KO |
NM-KO-190215 |
Clec4e |
Immune-related |
Clec4f-KO |
NM-KO-201483 |
Clec4f |
|
Clec4f-(IRES-CreERT2) |
NM-KI-200068 |
Clec4f |
Cre recombinase tool,Kupffer cell |
Clec4f-(IRES-DTRGFP) |
NM-KI-200070 |
Clec4f |
Cre recombinase tool,Kupffer cell |
Clec4f-(IRES-iCre-2A-tdTomato) |
NM-KI-200069 |
Clec4f |
Cre recombinase tool,Kupffer cell |
Clec4g-KO |
NM-KO-201484 |
Clec4g |
|
Clec4n-KO |
NM-KO-190217 |
Clec4n |
Immune-related |
Clec5a-KO |
NM-KO-190205 |
Clec5a |
Immune-related |
Clec7a-KO |
NM-KO-190219 |
Clec7a |
Immune-related |
Clec9a-(2A-CreERT2) |
NM-KI-200022 |
Clec9a |
Cre recombinase tool |
Clec9a-KO |
NM-KO-190204 |
Clec9a |
Immune-related |
Clic4-KO |
NM-KO-190938 |
Clic4 |
Female fertility, immune system, angiogenesis |
Clic5-KO |
NM-KO-190939 |
Clic5 |
Ciliated cell lesions, cataracts, glomerular defects, fat and energy metabolism |
Clint1-KO |
NM-KO-200131 |
Clint1 |
Therapeutic antibody target |
Clip1-CKO |
NM-CKO-205112 |
Clip1 |
|
Clip2-KO |
NM-KO-200930 |
Clip2 |
|
Cln3-KO |
NM-KO-201254 |
Cln3 |
|
Cln5-KO |
NM-KO-200931 |
Cln5 |
|
Clnk-KO |
NM-KO-201485 |
Clnk |
|
Clpsl2-KO |
NM-KO-205746 |
Clpsl2 |
secreted protein |
Clptm1-KO |
NM-KO-200132 |
Clptm1 |
Therapeutic antibody target |
Clptm1l-KO |
NM-KO-201486 |
Clptm1l |
|
Clta-KO |
NM-KO-190057 |
Clta |
Immune-related |
Cltrn-KO |
NM-KO-200672 |
Cltrn |
Involved in amino acid transport |
Clu-CKO |
NM-CKO-210035 |
Clu |
|
Clu-(2A-DreERT2) |
NM-KI-200025 |
Clu |
Dre recombinase tool |
Clu-KO |
NM-KO-190782 |
Clu |
Tumor progression,neurodegenerative disorders |
Cma1-KO |
NM-KO-190783 |
Cma1 |
Hematopoietic, immune |
Cmah-KO |
NM-KO-202032 |
Cmah |
|
Cmklr1-CKO |
NM-CKO-200336 |
Cmklr1 |
|
Cmklr1-KO |
NM-KO-200133 |
Cmklr1 |
Therapeutic antibody target |
Cmtr2-CKO |
NM-CKO-205134 |
Cmtr2 |
|
CMV-GFP |
NM-TG-00006 |
CMV-GFP |
Reporter mice,EGFP |
Cndp1-KO |
NM-KO-205440 |
Cndp1 |
secreted protein |
Cnga1-KO |
NM-KO-190941 |
Cnga1 |
Phototransduction, autosomal recessive inheritance (ARRP) disease of retinitis pigmentosa |
Cnga3-KO |
NM-KO-190942 |
Cnga3 |
Visual, cones, color blindness (rod monochromatic) and color blindness, smell |
Cnga4-KO |
NM-KO-190943 |
Cnga4 |
Olfactory, odor adaptation |
Cngb1-KO |
NM-KO-201255 |
Cngb1 |
|
Cngb3-KO |
NM-KO-190944 |
Cngb3 |
Vision, cones, color blindness 3, progressive cone dystrophy and juvenile macular degeneration (also known as Stargardt disease) |
Cnn2-KO |
NM-KO-201487 |
Cnn2 |
|
Cnot4-KO |
NM-KO-201488 |
Cnot4 |
|
Cnot6-KO |
NM-KO-200826 |
Cnot6 |
|
Cnpy3-KO |
NM-KO-202033 |
Cnpy3 |
|
Cnr1-CKO |
NM-CKO-200332 |
Cnr1 |
|
Cnr1-KO |
NM-KO-190945 |
Cnr1 |
Nervous system, behavior, depression, epilepsy |
Cnr2-KO |
NM-KO-210071 |
Cnr2 |
|
Cnst-KO |
NM-KO-200134 |
Cnst |
Therapeutic antibody target |
Cntn2-KO |
NM-KO-200135 |
Cntn2 |
Therapeutic antibody target |
Cntnap2-KO |
NM-KO-200932 |
Cntnap2 |
|
Coil-CKO |
NM-CKO-205252 |
Coil |
|
Col10a1-KO |
NM-KO-190258 |
Col10a1 |
Immune-related |
Col13a1-KO |
NM-KO-201489 |
Col13a1 |
|
Col16a1-KO |
NM-KO-205481 |
Col16a1 |
secreted protein |
Col22a1-KO |
NM-KO-205549 |
Col22a1 |
secreted protein |
Col24a1-KO |
NM-KO-205550 |
Col24a1 |
secreted protein |
Col26a1-KO |
NM-KO-200136 |
Col26a1 |
Therapeutic antibody target |
Col28a1-KO |
NM-KO-205626 |
Col28a1 |
secreted protein |
Col2a1-(2A-CreERT2) |
NM-KI-18029 |
Col2a1 |
Cre recombinase tool |
Col3a1-KO |
NM-KO-201256 |
Col3a1 |
|
Col4a1-(2A-EGFP) |
NM-KI-210002 |
Col4a1 |
Fluorescence Tracer Mice |
Col4a5-(R373X) |
NM-KI-200296 |
Col4a5 |
|
Col4a5-(R471X) |
NM-KI-200183 |
Col4a5 |
Alport syndrome research |
Col5a1-KO |
NM-KO-201257 |
Col5a1 |
|
Col5a3-KO |
NM-KO-200137 |
Col5a3 |
Therapeutic antibody target |
Col6a1-KO |
NM-KO-200138 |
Col6a1 |
Therapeutic antibody target |
Col6a3-KO |
NM-KO-200827 |
Col6a3 |
|
Col6a5-KO |
NM-KO-205640 |
Col6a5 |
secreted protein |
Col6a6-KO |
NM-KO-205624 |
Col6a6 |
secreted protein |
Col9a1-KO |
NM-KO-200933 |
Col9a1 |
|
Col9a2-KO |
NM-KO-205446 |
Col9a2 |
secreted protein |
Col9a3-KO |
NM-KO-205447 |
Col9a3 |
secreted protein |
Colca2-KO |
NM-KO-201490 |
Colca2 |
|
Colec10-KO |
NM-KO-205469 |
Colec10 |
secreted protein |
Colec11-KO |
NM-KO-201491 |
Colec11 |
|
Colq-KO |
NM-KO-201258 |
Colq |
|
Commd4-KO |
NM-KO-191136 |
Commd4 |
|
Cop1-KO |
NM-KO-190058 |
Cop1 |
Immune-related |
Copa-KO |
NM-KO-205457 |
Copa |
secreted protein |
Cops5-CKO |
NM-CKO-200306 |
Cops5 |
|
Cops7a-KO |
NM-KO-201492 |
Cops7a |
|
Cops8-KO |
NM-KO-202034 |
Cops8 |
|
Coq10a-KO |
NM-KO-200139 |
Coq10a |
Therapeutic antibody target |
Coq8a-KO |
NM-KO-200934 |
Coq8a |
|
Coq9-KO |
NM-KO-201259 |
Coq9 |
|
Coro1a-KO |
NM-KO-201493 |
Coro1a |
|
Cort-KO |
NM-KO-190059 |
Cort |
Immune-related |
Cox11-KO |
NM-KO-201141 |
Cox11 |
|
Cox15-KO |
NM-KO-202035 |
Cox15 |
|
Cox4i2-KO |
NM-KO-201494 |
Cox4i2 |
|
Cox6a1-KO |
NM-KO-200935 |
Cox6a1 |
|
Cox7a1-KO |
NM-KO-201260 |
Cox7a1 |
|
R26-(CAG-RSR-Cox8a-tdTomato) |
NM-KI-200050 |
Cox8a |
Mitochondrial tracing |
Cpa2-KO |
NM-KO-205482 |
Cpa2 |
secreted protein |
Cpa3-(CreERT2) |
NM-KI-200005 |
Cpa3 |
Cre recombinase tool |
Cpa3-KO |
NM-KO-190784 |
Cpa3 |
Hematopoietic, immune |
Cpa4-KO |
NM-KO-205456 |
Cpa4 |
secreted protein |
Cpa5-KO |
NM-KO-205483 |
Cpa5 |
secreted protein |
Cpa6-KO |
NM-KO-205441 |
Cpa6 |
secreted protein |
Cpb1-KO |
NM-KO-205445 |
Cpb1 |
secreted protein |
Cpd-KO |
NM-KO-190670 |
Cpd |
Wnt signaling pathway |
Cpe-KO |
NM-KO-190671 |
Cpe |
type 2 diabetes |
Cpeb3-CKO |
NM-CKO-205113 |
Cpeb3 |
|
Cplx2-KO |
NM-KO-200936 |
Cplx2 |
|
Cpm-KO |
NM-KO-190060 |
Cpm |
Immune-related |
Cpn2-KO |
NM-KO-205487 |
Cpn2 |
secreted protein |
Cpne1-KO |
NM-KO-200765 |
Cpne1 |
|
Cpne5-KO |
NM-KO-201495 |
Cpne5 |
|
Cpox-KO |
NM-KO-200828 |
Cpox |
|
Cpq-KO |
NM-KO-205425 |
Cpq |
secreted protein |
Cps1-KO |
NM-KO-201261 |
Cps1 |
|
Cpt1a-CKO |
NM-CKO-00056 |
Cpt1a |
Circadian Clock,Fatty acid metabolism,Carnitine Palmitoyltransferase IA Deficiency |
Cpt2-KO |
NM-KO-201496 |
Cpt2 |
|
Cptp-KO |
NM-KO-190061 |
Cptp |
Immune-related |
Cpxm1-KO |
NM-KO-205522 |
Cpxm1 |
secreted protein |
Cpxm2-KO |
NM-KO-205544 |
Cpxm2 |
secreted protein |
Cpz-KO |
NM-KO-205478 |
Cpz |
secreted protein |
Cr2-CKO |
NM-CKO-200331 |
Cr2 |
Associated with susceptibility to systemic lupus erythematosus type 9 |
Cr2-KO |
NM-KO-190185 |
Cr2 |
Immune-related |
Crabp1-M2rtTA |
NM-KI-190118 |
Crabp1 |
Tool Mice |
Crb1-KO |
NM-KO-190946 |
Crb1 |
Visual, retinopathy, photoreceptor cell development |
Crbn-(I391V) |
NM-KI-200331 |
Crbn |
|
Creb1-KO |
NM-KO-190947 |
Creb1 |
Nervous system, circadian rhythm, long-term memory, fear, sensory neurons, etc. |
Creb3l3-KO |
NM-KO-201497 |
Creb3l3 |
|
Crebbp-CKO |
NM-CKO-190016 |
Crebbp |
Epigenetic |
Creg2-KO |
NM-KO-205671 |
Creg2 |
secreted protein |
Crem-KO |
NM-KO-190062 |
Crem |
Immune-related |
Crh-CKO |
NM-CKO-200089 |
Crh |
Signal transduction and circadian rhythm related gene related research through GPCR |
Crh-(IRES-iCre) |
NM-KI-200104 |
Crh |
Cre recombinase tool |
Crisp2-KO |
NM-KO-205467 |
Crisp2 |
secreted protein |
Crisp3-KO |
NM-KO-205521 |
Crisp3 |
secreted protein |
Crispld1-KO |
NM-KO-205599 |
Crispld1 |
secreted protein |
Crk-CKO |
NM-CKO-200090 |
Crk |
Research on CCR5 Pathway and NGF Pathway in Macrophages |
Crlf2-KO |
NM-KO-190785 |
Crlf2 |
Hematopoietic, immune |
Crocc-KO |
NM-KO-201498 |
Crocc |
|
Crp-KO |
NM-KO-201499 |
Crp |
|
Crtam-KO |
NM-KO-201500 |
Crtam |
|
Crtap-KO |
NM-KO-200937 |
Crtap |
|
Crtc1-CKO |
NM-CKO-205135 |
Crtc1 |
|
CSF1&CSF1R-HU |
NM-HU-200273 |
Csf1,Csf1r |
|
CSF1-HU |
NM-HU-190043 |
Csf1 |
Immunotherapy,cancer research,drug screening |
Csf1-KO |
NM-KO-190063 |
Csf1 |
Immune-related |
Csf1r-CKO |
NM-CKO-200091 |
Csf1r |
Study on the relationship between hematopoietic cell lineage and ERK signaling |
CSF1R-HU |
NM-HU-190074 |
Csf1r |
Immunotherapy,Cancer research,Drug screening |
Csf1r-KO |
NM-KO-190786 |
Csf1r |
Hodgkin lymphoma |
Csf1r-(IRES-iCre) |
NM-KI-190026 |
Csf1r |
Cre recombinase tool |
CSF2-HU(M-NSG) |
NM-NSG-008 |
Csf2 |
Immunotherapy,drug screening |
Csf2-KO |
NM-KO-190532 |
Csf2 |
Growth Factors,NF-KB pathway,Allergy and Asthma, |
CSF2-HU |
NM-HU-190046 |
Csf2 |
Immunotherapy,cancer research,drug screening |
Csf2ra-KO |
NM-KO-200140 |
Csf2ra |
Therapeutic antibody target |
Csf2rb-KO |
NM-KO-190787 |
Csf2rb |
Respiratory system |
Csf2rb2-(2A-Cre) |
NM-KI-210001 |
Csf2rb2 |
Cre tool mice |
Csf2rb2-KO |
NM-KO-200829 |
Csf2rb2 |
|
Csf3-KO |
NM-KO-190533 |
Csf3 |
Growth Factors,NF-KB pathway,Allergy and Asthma, |
Csf3r-KO |
NM-KO-190788 |
Csf3r |
Congenital neutropenia |
Csmd1-KO |
NM-KO-200938 |
Csmd1 |
|
Csnk1e-KO |
NM-KO-190948 |
Csnk1e |
Nervous system,circadian rhythm |
Csnk2a2-KO |
NM-KO-200939 |
Csnk2a2 |
|
Cspg4-KO |
NM-KO-200141 |
Cspg4 |
Therapeutic antibody target |
Cspg4-(2A-DreERT2) |
NM-KI-190038 |
Cspg4 |
Dre recombinase tool |
Cspg5-KO |
NM-KO-200142 |
Cspg5 |
Therapeutic antibody target |
Cst11-KO |
NM-KO-205406 |
Cst11 |
secreted protein |
Cst8-KO |
NM-KO-205579 |
Cst8 |
secreted protein |
Cstb-KO |
NM-KO-201501 |
Cstb |
|
Cstl1-KO |
NM-KO-205667 |
Cstl1 |
secreted protein |
Ctbs-KO |
NM-KO-201502 |
Ctbs |
|
Ctc1-KO |
NM-KO-202036 |
Ctc1 |
|
Ctcf-CKO |
NM-CKO-200031 |
Ctcf |
Cancer research |
Ctcfl-KO |
NM-KO-190259 |
Ctcfl |
Immune-related |
Ctf1-KO |
NM-KO-190546 |
Ctf1 |
|
Cth-CKO |
NM-CKO-200274 |
Cth |
|
Cth-(Luc) |
NM-KI-00004 |
Cth |
homeostasis,liver,renal function related research and Cystathioninuria study |
CTLA4&CD28-HU |
NM-HU-200226 |
Ctla4,Cd28 |
|
Ctla4-KO |
NM-KO-202037 |
Ctla4 |
|
CTLA4-HU |
NM-HU-190078 |
CTLA4 |
Immunotherapy,cancer research,drug screening |
CTLA4-HU |
NM-HU-190038 |
Ctla4 |
Immunotherapy,cancer research,drug screening |
CTLA4-HU |
NM-HU-00014 |
Ctla4 |
cancer research,Immunotherapy,drug screening; |
PD-L1&CTLA4-HU |
NM-HU-00102 |
Ctla4,Cd274 |
Immunotherapy,cancer research,drug screening |
Ctnnal1-(2A-Cre) |
NM-KI-200016 |
Ctnnal1 |
Cre tool mouse |
Ctnnb1-CKO |
NM-CKO-200154 |
Ctnnb1 |
MicroRNA and CDK-mediated phosphorylation and Cdc6 removal in cardiomyocyte hypertrophy |
Ctnnb1-KO |
NM-KO-190634 |
Ctnnb1 |
colorectal cancer (CRC), pilomatrixoma (PTR), medulloblastoma (MDB), and ovarian cancer |
Ctns-KO |
NM-KO-200940 |
Ctns |
|
Ctrb1-KO |
NM-KO-205503 |
Ctrb1 |
secreted protein |
Ctsb-KO |
NM-KO-202038 |
Ctsb |
|
Ctsc-KO |
NM-KO-190789 |
Ctsc |
Papillon-Lefevre syndrome |
Ctse-KO |
NM-KO-200830 |
Ctse |
|
Ctsg-KO |
NM-KO-202039 |
Ctsg |
|
Ctsk-(2A-CreERT2) |
NM-KI-200067 |
Ctsk |
Cre recombinase tool |
Ctsk-(2A-Cre) |
NM-KI-190019 |
Ctsk |
Cre recombinase tool |
Ctsm-KO |
NM-KO-201503 |
Ctsm |
|
Ctss-KO |
NM-KO-200143 |
Ctss |
Therapeutic antibody target |
Cttnbp2-KO |
NM-KO-201504 |
Cttnbp2 |
|
Cubn-(sGFP-2A-nlacZ) |
NM-KI-200197 |
Cubn |
Fluorescence Tracer Mice |
Cuedc1-KO |
NM-KO-201142 |
Cuedc1 |
|
Cuedc2-KO |
NM-KO-201505 |
Cuedc2 |
|
Cul2-KO |
NM-KO-190949 |
Cul2 |
|
Cul5-KO |
NM-KO-202040 |
Cul5 |
|
Cuzd1-KO |
NM-KO-200144 |
Cuzd1 |
Therapeutic antibody target |
Cx3cl1-KO |
NM-KO-190064 |
Cx3cl1 |
Immune-related |
Cx3cr1-(creERT2) |
NM-KI-200157 |
Cx3cr1 |
Cre recombinase tool |
Cx3cr1-(iCre) |
NM-KI-200079 |
Cx3cr1 |
Cre recombinase tool, the mononuclear phagocyte system |
Cx3cr1-KO |
NM-KO-190065 |
Cx3cr1 |
Immune-related |
Cxcl10-KO |
NM-KO-190066 |
Cxcl10 |
Immune-related |
Cxcl11-KO |
NM-KO-190522 |
Cxcl11 |
Chemokines |
Cxcl12-CKO |
NM-CKO-200155 |
Cxcl12 |
Research on GPCR signal transduction and CCR5 pathway in macrophages |
Cxcl12-KO |
NM-KO-190523 |
Cxcl12 |
Cytokines, embryogenesis, immune surveillance, inflammation response, tissue homeostasis, and tumor growth and metastasis. |
Cxcl13-KO |
NM-KO-190067 |
Cxcl13 |
Immune-related |
Cxcl15-KO |
NM-KO-200660 |
Cxcl15 |
|
Cxcl16-KO |
NM-KO-190524 |
Cxcl16 |
Chemokines |
Cxcl17-KO |
NM-KO-205620 |
Cxcl17 |
secreted protein |
Cxcl2-KO |
NM-KO-205466 |
Cxcl2 |
secreted protein |
Cxcl3-KO |
NM-KO-205477 |
Cxcl3 |
secreted protein |
Cxcl5-KO |
NM-KO-190525 |
Cxcl5 |
Chemokines, lung inflammation |
Cxcl9-KO |
NM-KO-190069 |
Cxcl9 |
Immune-related |
CXCR1-HU |
NM-HU-2000024 |
Cxcr1 |
Immunotherapy,drug screening |
Cxcr1-KO |
NM-KO-190068 |
Cxcr1 |
Immune-related |
CXCR2-HU |
NM-HU-18025 |
Cxcr2 |
Immunotherapy,Cancer research,Drug screening |
CXCR3-HU |
NM-HU-200219 |
Cxcr3 |
Immune-related; drug screening |
Cxcr3-KO |
NM-KO-190071 |
Cxcr3 |
Immune-related |
Cxcr4-CKO |
NM-CKO-200156 |
Cxcr4 |
Research on GPCR signal transduction and CCR5 pathway in macrophages |
CXCR4-HU |
NM-HU-2000081 |
Cxcr4 |
Immunotherapy,drug screening |
Cxcr4-KO |
NM-KO-190072 |
Cxcr4 |
Immune-related |
Cxcr5-KO |
NM-KO-190073 |
Cxcr5 |
Immune-related |
Cyb561d2-KO |
NM-KO-201506 |
Cyb561d2 |
|
Cyb5d2-KO |
NM-KO-200145 |
Cyb5d2 |
Therapeutic antibody target |
Cyb5r4-KO |
NM-KO-200941 |
Cyb5r4 |
|
Cyba-KO |
NM-KO-191171 |
Cyba |
Mutations in this gene are associated with autosomal recessive chronic granulomatous disease (CGD) |
Cybb-KO |
NM-KO-18031 |
Cybb |
CGD, inflammatory |
Cyp11b1-KO |
NM-KO-200942 |
Cyp11b1 |
|
Cyp19a1-CKO |
NM-CKO-210026 |
Cyp19a1 |
|
Cyp1a1-KO |
NM-KO-201507 |
Cyp1a1 |
|
Cyp1a1-Cyp1a2-KO |
NM-KO-18018 |
Cyp1a1,Cyp1a2 |
|
Cyp1b1-KO |
NM-KO-200943 |
Cyp1b1 |
|
Cyp2c cluster-KO |
NM-KO-18019 |
Cyp2c cluster |
drug development |
R26-(Liver-CYP3A4) |
NM-KI-18032 |
CYP3A4 |
metabolism |
R26-(Gut-CYP3A4) |
NM-KI-18033 |
CYP3A4 |
metabolism |
Cyp3a-KO |
NM-KO-190427 |
Cyp3a57 |
|
Cyp3a-KO |
NM-KO-18056 |
Cyp3a57 |
|
Cyp4a10-KO |
NM-KO-200146 |
Cyp4a10 |
Therapeutic antibody target |
Cyp4v3-KO |
NM-KO-200711 |
Cyp4v3 |
|
Cyp51-KO |
NM-KO-202041 |
Cyp51 |
|
Cyp7a1-KO |
NM-KO-202042 |
Cyp7a1 |
|
Cysltr1-CKO |
NM-CKO-210060 |
Cysltr1 |
|
Cysltr1-KO |
NM-KO-190790 |
Cysltr1 |
Asthma,cancer |
Cysltr2-CKO |
NM-CKO-205163 |
Cysltr2 |
|
Cytl1-KO |
NM-KO-201508 |
Cytl1 |
|
D630045J12Rik-KO |
NM-KO-201509 |
D630045J12Rik |
|
D6Wsu163e-KO |
NM-KO-201510 |
D6Wsu163e |
|
Dab2ip-KO |
NM-KO-200147 |
Dab2ip |
Therapeutic antibody target |
Dag1-KO |
NM-KO-200148 |
Dag1 |
Therapeutic antibody target |
Dapp1-KO |
NM-KO-201511 |
Dapp1 |
|
Dbnl-KO |
NM-KO-201512 |
Dbnl |
|
Dbt-KO |
NM-KO-200633 |
Dbt |
Studies on degradation and metabolism of valine, leucine and isoleucine |
Dbx1-(IRES-CreERT2) |
NM-KI-200103 |
Dbx1 |
Cre recombinase tool |
Dcaf12l2-CKO |
NM-CKO-205164 |
Dcaf12l2 |
|
Dcaf7-CKO |
NM-CKO-205251 |
Dcaf7 |
|
R26-(CAG-LSL-Avi-dCas9-IRES-EGFP) |
NM-KI-18031 |
dCas9 |
|
R26-(CAG-LSL-dCas9-VPR-IRES-EGFP-WPRE-pA) |
NM-KI-18004 |
dCas9 |
gene regulation tool,CRISPRa |
R26-e(CAG-LSL-KRAB-dCas9-IRES-EGFP) |
NM-KI-18007 |
dCas9 |
CRISPRi,gene regulation tool |
CAG-LSL-dCas9-SPH |
NM-TG-00025 |
dCas9 |
gene regulation tool,CRISPRa |
Col1a1-(TRE3G-dCas9-VPR-eGFP-pA) |
NM-KI-00123 |
dCas9 |
gene regulation tool,CRISPRa |
Dcbld2-KO |
NM-KO-200687 |
Dcbld2 |
|
Dcc-CKO |
NM-CKO-205136 |
Dcc |
|
Dchs1-KO |
NM-KO-201262 |
Dchs1 |
|
Dck-KO |
NM-KO-201513 |
Dck |
|
Dclk1-KO |
NM-KO-200149 |
Dclk1 |
Therapeutic antibody target |
Dclre1c-KO |
NM-KO-201514 |
Dclre1c |
|
Dcstamp-KO |
NM-KO-200150 |
Dcstamp |
Therapeutic antibody target |
Dct-KO |
NM-KO-190074 |
Dct |
Immune-related |
Ddb2-CKO |
NM-CKO-205114 |
Ddb2 |
|
R26-(ddCas9) |
NM-KI-00063 |
ddCas9 |
gene editing,gene modification |
H11-(ddCre) |
NM-KI-00086 |
ddCre |
|
Ddhd2-KO |
NM-KO-200944 |
Ddhd2 |
|
Ddi2-CKO |
NM-CKO-210011 |
Ddi2 |
|
Ddit3-KO |
NM-KO-205039 |
Ddit3 |
|
Ddit3-CKO |
NM-CKO-200092 |
Ddit3 |
Studies on preimplantation embryos and signal transduction mediated by p38-alpha and p38-beta |
Ddit4-KO |
NM-KO-191072 |
Ddit4 |
Vision, retina; disc degeneration (IDD); cancer |
Ddit4l-KO |
NM-KO-191105 |
Ddit4l |
Autophagy, nervous system, muscle energy metabolism |
Ddost-KO |
NM-KO-201515 |
Ddost |
|
Ddr1-KO |
NM-KO-200151 |
Ddr1 |
Therapeutic antibody target |
Ddr2-CKO |
NM-CKO-200311 |
Ddr2 |
|
Ddr2-KO |
NM-KO-200152 |
Ddr2 |
Therapeutic antibody target |
Ddt-KO |
NM-KO-200663 |
Ddt |
|
Ddx4-KO |
NM-KO-200153 |
Ddx4 |
Therapeutic antibody target |
Ddx54-KO |
NM-KO-201516 |
Ddx54 |
|
Ddx58-KO |
NM-KO-18063 |
Ddx58 |
|
Ddx60-KO |
NM-KO-201517 |
Ddx60 |
|
Dedd-KO |
NM-KO-201518 |
Dedd |
|
Defa3-KO |
NM-KO-205409 |
Defa3 |
secreted protein |
Defa5-KO |
NM-KO-205407 |
Defa5 |
secreted protein |
Defb1-KO |
NM-KO-191137 |
Defb1 |
Defensin, cystic fibrosis, immune system |
Defb3-KO |
NM-KO-201519 |
Defb3 |
|
Degs2-KO |
NM-KO-200154 |
Degs2 |
Therapeutic antibody target |
Dennd1a-KO |
NM-KO-200155 |
Dennd1a |
Therapeutic antibody target |
Dennd3-KO |
NM-KO-190260 |
Dennd3 |
Immune-related |
Dennd4a-KO |
NM-KO-191138 |
Dennd4a |
may be involved in regulating the v-myc avian myelocytomatosis viral (MYC) oncogene. |
Depdc7-KO |
NM-KO-200831 |
Depdc7 |
|
Deptor-KO |
NM-KO-191106 |
Deptor |
Metabolism,cancer,immunity |
Des-KO |
NM-KO-190261 |
Des |
Immune-related |
Dexi-KO |
NM-KO-190262 |
Dexi |
Immune-related |
Dffb-KO |
NM-KO-201520 |
Dffb |
|
Dgcr2-Hira-KO |
NM-KO-18060 |
Dgcr2,Hira |
behavior, cardiovascular, mortality/aging, nervous system |
Dgcr8-KO |
NM-KO-205048 |
Dgcr8 |
|
Dgcr8-CKO |
NM-CKO-200157 |
Dgcr8 |
Research on the correlation between p53 effector and gene expression |
Dgka-KO |
NM-KO-190714 |
Dgka |
Immune related, T cell development related. |
Dgke-KO |
NM-KO-201143 |
Dgke |
|
Dgkz-KO |
NM-KO-190715 |
Dgkz |
They may be useful for studying the role of diacylglycerol in T cell development and function. |
Dhcr7-KO |
NM-KO-201263 |
Dhcr7 |
|
Dhh-KO |
NM-KO-200156 |
Dhh |
Therapeutic antibody target |
Dhrs11-KO |
NM-KO-205548 |
Dhrs11 |
secreted protein |
Dhrs13-KO |
NM-KO-200157 |
Dhrs13 |
Therapeutic antibody target |
Dhrs4-KO |
NM-KO-201521 |
Dhrs4 |
|
Dhrs7b-KO |
NM-KO-201101 |
Dhrs7b |
|
Dhrs7c-KO |
NM-KO-205669 |
Dhrs7c |
secreted protein |
Dhrsx-KO |
NM-KO-205431 |
Dhrsx |
secreted protein |
Dhtkd1-KO |
NM-KO-200945 |
Dhtkd1 |
|
Dhtkd1-(Y485X) |
NM-KI-00005 |
Dhtkd1 |
|
Dhx35-KO |
NM-KO-201522 |
Dhx35 |
|
Dhx58-KO |
NM-KO-201523 |
Dhx58 |
|
Diaph1-KO |
NM-KO-201524 |
Diaph1 |
|
Diaph2-KO |
NM-KO-190950 |
Diaph2 |
Heart development, brain development |
Dicer1-KO |
NM-KO-205035 |
Dicer1 |
|
Dicer1-CKO |
NM-CKO-200158 |
Dicer1 |
Hypoxia-mediated EMT, stem and gene expression related research |
Dido1-KO |
NM-KO-201144 |
Dido1 |
|
Dip2a-KO |
NM-KO-201525 |
Dip2a |
|
Dis3-CKO |
NM-CKO-205137 |
Dis3 |
|
Dkk2-KO |
NM-KO-200158 |
Dkk2 |
Therapeutic antibody target |
Dkk3-KO |
NM-KO-190674 |
Dkk3 |
Cancer-related genes |
Dleu2-KO |
NM-KO-201145 |
Dleu2 |
|
Dleu7-KO |
NM-KO-201146 |
Dleu7 |
|
Dlg4-KO |
NM-KO-190951 |
Dlg4 |
Nervous system, pain, space learning, depression |
DLL3-HU |
NM-HU-200231 |
Dll3 |
|
Dll3-KO |
NM-KO-201264 |
Dll3 |
|
DLL4-HU |
NM-HU-2000020 |
Dll4 |
Immunotherapy,drug screening |
Dlx3-CKO |
NM-CKO-200164 |
Dlx3 |
Study on the relationship between DNA binding transcription factor activity and chromatin binding |
Dlx5-KO |
NM-KO-201265 |
Dlx5 |
|
Dlx6-KO |
NM-KO-201266 |
Dlx6 |
|
Dmbt1-KO |
NM-KO-202043 |
Dmbt1 |
|
Dmd-KO |
NM-KO-200573 |
Dmd |
Duchenne muscular dystrophy research |
Dmd-(c.C2983T) |
NM-KI-18026 |
Dmd |
|
Dmkn-KO |
NM-KO-205601 |
Dmkn |
secreted protein |
Dmp1-KO |
NM-KO-200634 |
Dmp1 |
Research on the degradation of ECM proteoglycans and extracellular matrix |
Dmpk-KO |
NM-KO-200635 |
Dmpk |
Cardiac conduction and G protein signal transduction RAC1 in cellular processes |
Dmtf1-KO |
NM-KO-202044 |
Dmtf1 |
|
Dnah3-KO |
NM-KO-210041 |
Dnah3 |
|
Dnajb1-CKO |
NM-CKO-205165 |
Dnajb1 |
|
Dnajc11-KO |
NM-KO-201526 |
Dnajc11 |
|
Dnajc15-KO |
NM-KO-201527 |
Dnajc15 |
|
Dnajc19-CKO |
NM-CKO-205210 |
Dnajc19 |
|
Dnal1-KO |
NM-KO-201528 |
Dnal1 |
|
Dnhd1-KO |
NM-KO-200793 |
Dnhd1 |
|
Dnlz-KO |
NM-KO-200832 |
Dnlz |
|
Dnmt1-CKO |
NM-CKO-190046 |
Dnmt1 |
Epigenetic |
Dnmt3a-CKO |
NM-CKO-190047 |
Dnmt3a |
Epigenetic |
Dnmt3b-CKO |
NM-CKO-190017 |
Dnmt3b |
Epigenetic |
Dnmt3l-CKO |
NM-CKO-190018 |
Dnmt3l |
Epigenetic |
Dntt-KO |
NM-KO-201529 |
Dntt |
|
Doc2a-KO |
NM-KO-201147 |
Doc2a |
|
Dock2-KO |
NM-KO-201530 |
Dock2 |
|
Dock3-KO |
NM-KO-201531 |
Dock3 |
|
Dock6-KO |
NM-KO-190264 |
Dock6 |
Immune-related |
Dock8-KO |
NM-KO-201532 |
Dock8 |
|
Dok1-KO |
NM-KO-201533 |
Dok1 |
|
Dok2-KO |
NM-KO-201534 |
Dok2 |
|
Dpep3-KO |
NM-KO-200159 |
Dpep3 |
Therapeutic antibody target |
Dph2-KO |
NM-KO-201535 |
Dph2 |
|
Dpm2-KO |
NM-KO-201536 |
Dpm2 |
|
Dpp4-KO |
NM-KO-190791 |
Dpp4 |
Endocrine |
DPP4-HU |
NM-HU-190042 |
Dpp4 |
Immunotherapy,cancer research,drug screening |
Dpp7-KO |
NM-KO-205470 |
Dpp7 |
secreted protein |
Dpp8-CKO |
NM-CKO-00047 |
Dpp8 |
|
Dppa3-(Cre) |
NM-KI-00040 |
Dppa3 |
Cre recombinase tool |
Dpysl4-KO |
NM-KO-191139 |
Dpysl4 |
|
Dr1-KO |
NM-KO-190075 |
Dr1 |
Immune-related |
Drc3-KO |
NM-KO-200946 |
Drc3 |
|
Drd1-KO |
NM-KO-205028 |
Drd1 |
|
Drd1-CKO |
NM-CKO-200159 |
Drd1 |
Research on the Signal Transduction of Monoamine GPCR and GPCR |
Drd1-(2A-CreERT2-WPRE-pA) |
NM-KI-18016 |
Drd1 |
Cre recombinase tool |
Drd2-CKO |
NM-CKO-200160 |
Drd2 |
Research on the Signal Transduction of Monoamine GPCR and GPCR |
Drd2-KO |
NM-KO-190265 |
Drd2 |
Immune-related |
Drd3-KO |
NM-KO-190952 |
Drd3 |
Nervous system,hereditary primary tremor 1 |
CAG-Dre |
NM-TG-00026 |
Dre |
Dre recombinase tool |
Drg2-KO |
NM-KO-200947 |
Drg2 |
|
Dsc1-KO |
NM-KO-201537 |
Dsc1 |
|
Dsc2-KO |
NM-KO-200160 |
Dsc2 |
Therapeutic antibody target |
Dsg1a-KO |
NM-KO-200161 |
Dsg1a |
Therapeutic antibody target |
Dsg1b-KO |
NM-KO-200833 |
Dsg1b |
|
Dsg1c-KO |
NM-KO-200834 |
Dsg1c |
|
Dsg3-KO |
NM-KO-200162 |
Dsg3 |
Therapeutic antibody target |
Dsg4-KO |
NM-KO-200835 |
Dsg4 |
|
R26-(CAG-LSL-R-tdTomato-2A-DTR) |
NM-KI-210094 |
DTR |
Dre reporter |
R26-(CAG-RSR-tdTomato-2A-DTR) |
NM-KI-200191 |
DTR |
Dre reporter |
R26-(CAG-LSL-RSR-tdTomato-2A-DTR) |
NM-KI-190086 |
DTR |
Dre and Dre reporter |
Dtx1-KO |
NM-KO-190077 |
Dtx1 |
Immune-related |
Duoxa1-KO |
NM-KO-202045 |
Duoxa1 |
|
Duoxa2-KO |
NM-KO-202046 |
Duoxa2 |
|
Dusp10-KO |
NM-KO-201538 |
Dusp10 |
|
R26-(Dusp12) |
NM-KI-18038 |
Dusp12 |
|
Dusp12-KO |
NM-KO-18054 |
Dusp12 |
|
Dusp2-KO |
NM-KO-200163 |
Dusp2 |
Therapeutic antibody target |
Dusp3-KO |
NM-KO-200836 |
Dusp3 |
|
Dusp4-KO |
NM-KO-190792 |
Dusp4 |
hematopoietic, immune |
Dusp5-KO |
NM-KO-201539 |
Dusp5 |
|
Dusp6-KO |
NM-KO-202047 |
Dusp6 |
|
Dvl1-KO |
NM-KO-190675 |
Dvl1 |
Cancer-related genes |
Dydc1-KO |
NM-KO-200164 |
Dydc1 |
Therapeutic antibody target |
Dydc2-KO |
NM-KO-200664 |
Dydc2 |
Diseases associated with DYDC2 include Myofibrillar Myopathy and Arrhythmogenic Right Ventricular Cardiomyopathy. |
Dynll2-KO |
NM-KO-201149 |
Dynll2 |
|
Dyrk1a-CKO |
NM-CKO-200167 |
Dyrk1a |
Research on Notch Signaling Pathway (WikiPathways) and circadian rhythm related genes |
Dyrk1b-KO |
NM-KO-201540 |
Dyrk1b |
|
Dyrk4-KO |
NM-KO-190266 |
Dyrk4 |
Immune-related |
Dysf-KO |
NM-KO-200948 |
Dysf |
|
Dzank1-KO |
NM-KO-200165 |
Dzank1 |
Therapeutic antibody target |
E030018B13Rik-KO |
NM-KO-201150 |
E030018B13Rik |
|
E2f1-KO |
NM-KO-190623 |
E2f1 |
The protein encoded by this gene is a member of the E2F family of transcription factors. The E2F family plays a crucial role in the control of cell cycle and action of tumor suppressor proteins and is also a target of the transforming proteins of small DNA tumor viruses. This protein binds preferentially to retinoblastoma protein pRB in a cell-cycle dependent manner. It can mediate both cell proliferation and p53-dependent/independent apoptosis. |
E2f2-KO |
NM-KO-202048 |
E2f2 |
|
E2f4-KO |
NM-KO-202049 |
E2f4 |
|
E2f5-KO |
NM-KO-201267 |
E2f5 |
|
E330021D16Rik-KO |
NM-KO-190267 |
E330021D16Rik |
Immune-related |
Eapp-KO |
NM-KO-190560 |
Eapp |
Transcription and proliferation. |
Ebag9-KO |
NM-KO-201541 |
Ebag9 |
|
Ebf1-CKO |
NM-CKO-00065 |
Ebf1 |
not clear |
Ebi3-KO |
NM-KO-190076 |
Ebi3 |
Immune-related |
Ece1-KO |
NM-KO-201268 |
Ece1 |
|
Ecm2-KO |
NM-KO-205525 |
Ecm2 |
secreted protein |
Ecrg4-CKO |
NM-CKO-205241 |
Ecrg4 |
|
Eda-KO |
NM-KO-200167 |
Eda |
Therapeutic antibody target |
Eda2r-KO |
NM-KO-191162 |
Eda2r |
The protein encoded by this gene is a type III transmembrane protein of the TNFR (tumor necrosis factor receptor) superfamily |
Edar-KO |
NM-KO-200168 |
Edar |
Therapeutic antibody target |
Edc4-KO |
NM-KO-191130 |
Edc4 |
Pro-mRNA degradation |
Eddm3b-KO |
NM-KO-205695 |
Eddm3b |
secreted protein |
Edn2-CKO |
NM-CKO-205245 |
Edn2 |
|
Edn3-KO |
NM-KO-201269 |
Edn3 |
|
Eed-CKO |
NM-CKO-190019 |
Eed |
Epigenetic |
Efemp1-KO |
NM-KO-200840 |
Efemp1 |
|
Efhc1-KO |
NM-KO-200949 |
Efhc1 |
|
Efhd2-KO |
NM-KO-201542 |
Efhd2 |
|
Efna4-KO |
NM-KO-200169 |
Efna4 |
Therapeutic antibody target |
Efs-KO |
NM-KO-200950 |
Efs |
|
Eftud2-CKO |
NM-CKO-205138 |
Eftud2 |
|
Egf-KO |
NM-KO-190630 |
Egf |
certain cancers |
Egfl6-KO |
NM-KO-200170 |
Egfl6 |
Therapeutic antibody target |
H11-(EGFP) |
NM-KI-00066 |
EGFP |
gene tracing,Reporter mice,EGFP |
EGFR-HU |
NM-HU-200227 |
Egfr |
|
EGFR-HU |
NM-HU-200232 |
Egfr |
|
R26-(CAG-LSL-EGFR(T790M) -IRES-Luciferase-2A-tdTomato) |
NM-KI-190070 |
EGFR |
cancer research |
R26-(CAG-LSL-EGFR-IRES-luciferase-2A-tdTomato) |
NM-KI-190066 |
EGFR |
cancer research |
R26-(CAG-LSL-EGFR (L858R-T790M-C797S)-IRES-luciferase-2A-tdTomato) |
NM-KI-190067 |
EGFR |
cancer research |
R26-(CAG-LSL-EGFR (L858R-T790M)-IRES-luciferase-2A-tdTomato) |
NM-KI-190068 |
EGFR |
cancer research |
R26-(CAG-LSL-EGFR(L858R)-IRES-Luciferase-2A-tdTomato) |
NM-KI-190069 |
EGFR |
cancer research |
Egfr-KO |
NM-KO-190268 |
Egfr |
Immune-related |
Egfr-CKO |
NM-CKO-00133 |
Egfr |
cancer research, EGFR fuction study |
Egln2-KO |
NM-KO-191064 |
Egln2 |
Hypoxia-inducible factor-related protein,tumor,breast cancer |
Egr2-(iCre) |
NM-KI-200132 |
Egr2 |
Cre recombinase tool |
Ehd2-CKO |
NM-CKO-205166 |
Ehd2 |
|
Ehd4-KO |
NM-KO-190269 |
Ehd4 |
Immune-related |
Ehf-CKO |
NM-CKO-200338 |
Ehf |
|
Ehmt1-CKO |
NM-CKO-190020 |
Ehmt1 |
Epigenetic |
Ehmt2-CKO |
NM-CKO-190048 |
Ehmt2 |
Epigenetic |
Eif1ax-CKO |
NM-CKO-205139 |
Eif1ax |
|
Eif2ak3-CKO |
NM-CKO-200161 |
Eif2ak3 |
Autophagy, animal and respiratory electron transport |
Eif3e-CKO |
NM-CKO-205140 |
Eif3e |
|
Eif4b-KO |
NM-KO-191114 |
Eif4b |
cancer |
Eif4e-KO |
NM-KO-191115 |
Eif4e |
Tumor, proto-oncogene |
Eif4ebp1-KO |
NM-KO-191088 |
Eif4ebp1 |
Tumor development,tumor hypoxia; metabolism |
Eif4ebp2-KO |
NM-KO-191121 |
Eif4ebp2 |
Cell proliferation and differentiation, viral infection, nervous system, synaptic transmission, autism, muscle homeostasis |
Eif4ebp3-KO |
NM-KO-201543 |
Eif4ebp3 |
|
Eif4h-KO |
NM-KO-201151 |
Eif4h |
|
Eif5b-KO |
NM-KO-191140 |
Eif5b |
|
Elane-KO |
NM-KO-201544 |
Elane |
|
Elf1-KO |
NM-KO-190270 |
Elf1 |
Immune-related |
Elf4-CKO |
NM-CKO-205115 |
Elf4 |
|
Elk1-KO |
NM-KO-190615 |
Elk1 |
This gene is a member of the Ets family of transcription factors and of the ternary complex factor (TCF) subfamily. Proteins of the TCF subfamily form a ternary complex by binding to the the serum response factor and the serum response element in the promoter of the c-fos proto-oncogene. |
Elmo1-KO |
NM-KO-190953 |
Elmo1 |
Male germ cells support cell phagocytosis |
Eloa-CKO |
NM-CKO-190070 |
Eloa |
|
Elobl-KO |
NM-KO-201152 |
Elobl |
|
Elovl3-KO |
NM-KO-201545 |
Elovl3 |
|
Elovl6-KO |
NM-KO-200802 |
Elovl6 |
|
Emb-KO |
NM-KO-200171 |
Emb |
Therapeutic antibody target |
Emc10-CKO |
NM-CKO-00084 |
Emc10 |
cancer,nervous system |
Emcn-KO |
NM-KO-205551 |
Emcn |
secreted protein |
Emid1-KO |
NM-KO-190558 |
Emid1 |
|
Emilin3-KO |
NM-KO-205670 |
Emilin3 |
secreted protein |
Eml1-KO |
NM-KO-190793 |
Eml1 |
Usher syndrome |
R26-(CAG-LSL-EML4-ALK-IRES-Luciferase-2A-tdTomato) |
NM-KI-190072 |
EML4-ALK |
cancer research |
Emp2-CKO |
NM-CKO-200074 |
Emp2 |
Protein kinase binding and kinase binding related research |
Emp2-KO |
NM-KO-200172 |
Emp2 |
Therapeutic antibody target |
Emx1-(IRES-Cre) |
NM-KI-200149 |
Emx1 |
Cre recombinase tool |
En2-KO |
NM-KO-200173 |
En2 |
Therapeutic antibody target |
Enam-KO |
NM-KO-200951 |
Enam |
|
Endod1-KO |
NM-KO-205655 |
Endod1 |
secreted protein |
Eng-KO |
NM-KO-201270 |
Eng |
|
Enkur-KO |
NM-KO-201546 |
Enkur |
|
Eno2-(CreERT2) |
NM-KI-200011 |
Eno2 |
Cre recombinase tool |
Eno2-(iCre) |
NM-KI-200012 |
Eno2 |
Cre recombinase tool |
Enox1-KO |
NM-KO-205557 |
Enox1 |
secreted protein |
Enpep-CKO |
NM-CKO-205141 |
Enpep |
|
Enpp1-KO |
NM-KO-200618 |
Enpp1 |
NAD metabolism and Riboflavin metabolism research; Cole Disease and Hypophosphatemic Rickets research. |
Enpp3-KO |
NM-KO-200174 |
Enpp3 |
Therapeutic antibody target |
Enpp5-KO |
NM-KO-205530 |
Enpp5 |
secreted protein |
Enpp6-KO |
NM-KO-00020 |
Enpp6 |
Ether lipid metabolism |
ENTPD1-HU |
NM-HU-200223 |
Entpd1 |
tumor research; drug screening |
Entpd1-KO |
NM-KO-190078 |
Entpd1 |
Immune-related |
Entpd2-KO |
NM-KO-200175 |
Entpd2 |
Therapeutic antibody target |
Entpd3-KO |
NM-KO-200176 |
Entpd3 |
Therapeutic antibody target |
Entpd5-KO |
NM-KO-200177 |
Entpd5 |
Therapeutic antibody target |
Entpd6-KO |
NM-KO-200178 |
Entpd6 |
Therapeutic antibody target |
Entpd7-KO |
NM-KO-201547 |
Entpd7 |
|
Eomes-CKO |
NM-CKO-200162 |
Eomes |
Research on the development and heterogeneity of ILC family and the differentiation pathway of innate lymphoid cells |
Ep300-CKO |
NM-CKO-190021 |
Ep300 |
Epigenetic |
Epas1-KO |
NM-KO-205024 |
Epas1 |
|
Epas1-CKO |
NM-CKO-200163 |
Epas1 |
CDK-mediated phosphorylation, Cdc6 removal, and GPCR signaling related research |
Epb41-KO |
NM-KO-201548 |
Epb41 |
|
Epb42-KO |
NM-KO-200179 |
Epb42 |
Therapeutic antibody target |
Epcam-(CreERT2) |
NM-KI-00084 |
Epcam |
|
Epdr1-KO |
NM-KO-205422 |
Epdr1 |
secreted protein |
Epgn-KO |
NM-KO-201549 |
Epgn |
|
Epha1-KO |
NM-KO-191127 |
Epha1 |
Nervous system,cancer |
Epha10-KO |
NM-KO-200180 |
Epha10 |
Therapeutic antibody target |
Epha2-KO |
NM-KO-200181 |
Epha2 |
Therapeutic antibody target |
Epha4-KO |
NM-KO-200182 |
Epha4 |
Therapeutic antibody target |
Epha5-KO |
NM-KO-200183 |
Epha5 |
Therapeutic antibody target |
Epha6-KO |
NM-KO-201550 |
Epha6 |
|
Epha7-KO |
NM-KO-200184 |
Epha7 |
Therapeutic antibody target |
Ephb2-KO |
NM-KO-190271 |
Ephb2 |
Immune-related |
Ephb3-KO |
NM-KO-200185 |
Ephb3 |
Therapeutic antibody target |
Ephb6-KO |
NM-KO-200851 |
Ephb6 |
|
Ephx1-CKO |
NM-CKO-210007 |
Ephx1 |
|
Ephx2-KO |
NM-KO-190954 |
Ephx2 |
Endocrine and metabolic systems, blood pressure, arachidonic acid metabolism |
Epm2a-KO |
NM-KO-200952 |
Epm2a |
|
Epn3-KO |
NM-KO-201153 |
Epn3 |
|
Eppin-KO |
NM-KO-205577 |
Eppin |
secreted protein |
Eps15-CKO |
NM-CKO-205142 |
Eps15 |
|
Epx-(Cre) |
NM-KI-200211 |
Epx |
Cre tool mice |
Epx-KO |
NM-KO-190794 |
Epx |
Eosinophil peroxidase deficiency |
Epyc-KO |
NM-KO-201552 |
Epyc |
|
Erap1-KO |
NM-KO-201553 |
Erap1 |
|
ERBB2-HU |
NM-HU-200115 |
Erbb2 |
Immune-related; tumor research; drug screening |
R26-(CAG-LSL-ERBB2(exon20 insertion)-IRES-Luciferase-2A-EGFP) |
NM-KI-190071 |
ERBB2 |
cancer research |
HER3-HU |
NM-HU-200234 |
Erbb3 |
|
Erbb4-(I712M) |
NM-KI-200283 |
Erbb4 |
|
Erbb4-(R1259W) |
NM-KI-200282 |
Erbb4 |
|
Erbb4-(R927Q) |
NM-KI-200281 |
Erbb4 |
|
Ercc5-KO |
NM-KO-201271 |
Ercc5 |
|
Ercc6-KO |
NM-KO-200953 |
Ercc6 |
|
Ercc8-KO |
NM-KO-200954 |
Ercc8 |
|
Ereg-KO |
NM-KO-200770 |
Ereg |
|
Ereg-KO |
NM-KO-200186 |
Ereg |
Therapeutic antibody target |
Erfe-KO |
NM-KO-200187 |
Erfe |
Therapeutic antibody target |
Ergic1-KO |
NM-KO-200188 |
Ergic1 |
Therapeutic antibody target |
Ermap-KO |
NM-KO-200189 |
Ermap |
Therapeutic antibody target |
Ern1-CKO |
NM-CKO-00077 |
Ern1 |
|
Ern2-KO |
NM-KO-201554 |
Ern2 |
|
Ero1l-KO |
NM-KO-191073 |
Ero1l |
Endoplasmic reticulum stress-induced apoptosis, cell response to hypoxia |
Errfi1-KO |
NM-KO-202050 |
Errfi1 |
|
Esam-KO |
NM-KO-201555 |
Esam |
|
Esco2-CKO |
NM-CKO-200093 |
Esco2 |
CDK-mediated phosphorylation, Cdc6 removal, and cell cycle related research in mitosis |
Esm1-KO |
NM-KO-205465 |
Esm1 |
secreted protein |
Espn-KO |
NM-KO-201556 |
Espn |
|
Esr1-KO |
NM-KO-200651 |
Esr1 |
Study on protein metabolism and LKB1 signaling events |
Esr1-CKO |
NM-CKO-200175 |
Esr1 |
Study on protein metabolism and LKB1 signaling events |
Esr1-(2A-iCre) |
NM-KI-200164 |
Esr1 |
Cre recombinase tool |
Esr1-CKO |
NM-CKO-200024 |
Esr1 |
Cancer research |
Esr1-KO |
NM-KO-190631 |
Esr1 |
breast cancer, endometrial cancer, and osteoporosis |
Esr2-KO |
NM-KO-200190 |
Esr2 |
Therapeutic antibody target |
Esrra-CKO |
NM-CKO-00039 |
Esrra |
Metabolism,Metabolism of lipids and lipoproteins,Mitochondrial biogenesis |
Esyt2-KO |
NM-KO-201557 |
Esyt2 |
|
Ethe1-KO |
NM-KO-201272 |
Ethe1 |
|
Etv1-(CreERT2) |
NM-KI-200105 |
Etv1 |
Cre recombinase tool |
Etv2-KO |
NM-KO-202051 |
Etv2 |
|
Etv4-CKO |
NM-CKO-200345 |
Etv4 |
|
Etv5-CKO |
NM-CKO-205130 |
Etv5 |
|
Etv6-CKO |
NM-CKO-200269 |
Etv6 |
|
Evc-KO |
NM-KO-201273 |
Evc |
|
Evc2-KO |
NM-KO-201274 |
Evc2 |
|
Exoc6b-CKO |
NM-CKO-00138 |
Exoc6b |
|
Ezh1-CKO |
NM-CKO-200343 |
Ezh1 |
|
R26-(CAG-LSL-EZH2(Y646N)-IRES-Luciferase-2A-tdTomato) |
NM-KI-190073 |
EZH2 |
cancer research |
Ezh2-CKO |
NM-CKO-190022 |
Ezh2 |
Epigenetic |
F11-HU |
NM-HU-210015 |
F11 |
drug screening |
F11-KO |
NM-KO-200191 |
F11 |
Therapeutic antibody target |
F11r-KO |
NM-KO-200192 |
F11r |
Therapeutic antibody target |
F12-HU |
NM-HU-210017 |
F12 |
drug screening |
F12-KO |
NM-KO-200193 |
F12 |
Therapeutic antibody target |
F2r-KO |
NM-KO-210015 |
F2r |
|
F2rl1-KO |
NM-KO-200838 |
F2rl1 |
|
F2rl3-KO |
NM-KO-200839 |
F2rl3 |
|
F8-KO |
NM-KO-200608 |
F8 |
Hemophilia A;HEMA |
F8-KO |
NM-KO-00012 |
F8 |
Hemophilia A;HEMA |
F9-KO |
NM-KO-200607 |
F9 |
Hemophilia B |
F9-KO |
NM-KO-18046 |
F9 |
factor IX (F9) function and gene therapy |
Fa2h-KO |
NM-KO-200955 |
Fa2h |
|
Faah-CKO |
NM-CKO-200333 |
Faah |
|
Faap100-KO |
NM-KO-190272 |
Faap100 |
Immune-related |
Fabp4-(2A-DreERT2) |
NM-KI-200060 |
Fabp4 |
Dre recombinase tool |
Fabp4-KO |
NM-KO-200194 |
Fabp4 |
Therapeutic antibody target |
Fads2-KO |
NM-KO-201558 |
Fads2 |
|
Faf1-KO |
NM-KO-191163 |
Faf1 |
Interaction of Fas ligand (TNFSF6) with the FAS antigen (TNFRSF6) mediates programmed cell death, also called apoptosis, in a number of organ systems. |
Fah-KO(M-NSG) |
NM-NSG-004 |
Fah |
Tyrosinemia type I research |
Fah-KO |
NM-KO-191202 |
Fah |
Tyrosinemia type I research |
Faim-KO |
NM-KO-202052 |
Faim |
|
Fam135b-CKO |
NM-CKO-205116 |
Fam135b |
|
Fam160a1-KO |
NM-KO-201559 |
Fam160a1 |
|
Fam162a-KO |
NM-KO-191090 |
Fam162a |
Apoptosis,tumor |
Fam163a-KO |
NM-KO-201560 |
Fam163a |
|
Fam180a-KO |
NM-KO-205689 |
Fam180a |
secreted protein |
Fam186a-CKO |
NM-CKO-205143 |
Fam186a |
|
Fam19a2-KO |
NM-KO-00045 |
Fam19a2 |
|
Fam207a-KO |
NM-KO-200956 |
Fam207a |
|
Fam209-KO |
NM-KO-201561 |
Fam209 |
|
Fam210a-KO |
NM-KO-202053 |
Fam210a |
|
Fam220a-KO |
NM-KO-190273 |
Fam220a |
Immune-related |
Fam24a-KO |
NM-KO-205723 |
Fam24a |
secreted protein |
Fam24b-KO |
NM-KO-205724 |
Fam24b |
secreted protein |
Fam3a-KO |
NM-KO-205574 |
Fam3a |
secreted protein |
Fam50a-KO |
NM-KO-200763 |
Fam50a |
|
Fam57b-KO |
NM-KO-201154 |
Fam57b |
|
Fam92a-KO |
NM-KO-200957 |
Fam92a |
|
Fan1-KO |
NM-KO-200958 |
Fan1 |
|
Fanca-CKO |
NM-CKO-205167 |
Fanca |
|
Fancc-CKO |
NM-CKO-205168 |
Fancc |
|
FAP-HU |
NM-HU-200233 |
Fap |
|
Fap-KO |
NM-KO-190079 |
Fap |
Immune-related |
Far2-KO |
NM-KO-200959 |
Far2 |
|
FAS-HU |
NM-HU-210007 |
Fas |
inmmue therapy;drug screening |
Fas-KO |
NM-KO-191206 |
Fas |
Immune-related |
Fas-KO |
NM-KO-190080 |
Fas |
Immune-related |
Fasl-KO |
NM-KO-190541 |
Fasl |
Cancer related;systemic lupus erythematosus related |
Fastk-KO |
NM-KO-201562 |
Fastk |
|
Fat2-KO |
NM-KO-190955 |
Fat2 |
Cell adhesion molecule,cell proliferation,cerebellar development |
Fat3-KO |
NM-KO-190956 |
Fat3 |
Visual, nervous system |
Fau-CKO |
NM-CKO-00048 |
Fau |
|
Fblim1-KO |
NM-KO-201563 |
Fblim1 |
|
Fbln2-KO |
NM-KO-200195 |
Fbln2 |
Therapeutic antibody target |
Fbln5-KO |
NM-KO-190274 |
Fbln5 |
Immune-related |
Fbln7-CKO |
NM-CKO-00120 |
Fbln7 |
|
Fbn1-(C1041G) |
NM-KI-200303 |
Fbn1 |
|
Fbn1-CKO |
NM-CKO-200325 |
Fbn1 |
|
Fbn2-CKO |
NM-CKO-205169 |
Fbn2 |
|
Fbp1-KO |
NM-KO-190796 |
Fbp1 |
Hypoglycemia and metabolic acidosis |
Fbxl16-KO |
NM-KO-190797 |
Fbxl16 |
Mouse Aging |
Fbxl19-KO |
NM-KO-201564 |
Fbxl19 |
|
Fbxo10-KO |
NM-KO-201565 |
Fbxo10 |
|
Fbxo33-CKO |
NM-CKO-205243 |
Fbxo33 |
|
Fbxo36-KO |
NM-KO-201566 |
Fbxo36 |
|
Fbxo4-KO |
NM-KO-202054 |
Fbxo4 |
|
Fbxo42-CKO |
NM-CKO-200263 |
Fbxo42 |
|
Fbxo9-KO |
NM-KO-190957 |
Fbxo9 |
|
Fbxw11-KO |
NM-KO-190696 |
Fbxw11 |
phosphorylation-dependent ubiquitination |
Fbxw2-KO |
NM-KO-200797 |
Fbxw2 |
|
Fbxw24-CKO |
NM-CKO-200292 |
Fbxw24 |
|
Fbxw26-KO |
NM-KO-201567 |
Fbxw26 |
|
Fbxw7-CKO |
NM-CKO-200327 |
Fbxw7 |
|
Fcamr-KO |
NM-KO-201568 |
Fcamr |
|
Fcer1a-KO |
NM-KO-190798 |
Fcer1a |
allergic response |
Fcer1g-KO |
NM-KO-190187 |
Fcer1g |
Immune-related |
Fcer2a-KO |
NM-KO-190799 |
Fcer2a |
immune related |
Fcgbp-KO |
NM-KO-205575 |
Fcgbp |
secreted protein |
FCGR1A-HU |
NM-HU-2000072 |
Fcgr1 |
Immunotherapy,drug screening |
FCGR1B-HU |
NM-HU-2000040 |
Fcgr1 |
Immunotherapy,drug screening |
Fcgr1-KO |
NM-KO-18033 |
Fcgr1 |
immunodeficiency, immune system |
FCGR2B&OX40-HU |
NM-HU-200265 |
Fcgr2b,OX40 |
|
FCGR2A-HU |
NM-HU-2000071 |
Fcgr2b |
Immunotherapy,drug screening |
FCGR2B-HU |
NM-HU-2000010 |
Fcgr2b |
Immunotherapy,cancer research,drug screening |
Fcgr2b/Fcgr3/Fcgr4-KO |
NM-KO-18037 |
Fcgr2b,Fcgr3,Fcgr4 |
inflammation,autoimmunity |
Fcgr2b-KO |
NM-KO-00130 |
Fcgr2b |
immune system |
FCGR2B&CD40-HU |
NM-HU-200262 |
Fcgr2b,Cd40 |
|
CD16-HU |
NM-HU-200229 |
Fcgr3 |
|
Fcgr3-KO |
NM-KO-190189 |
Fcgr3 |
Immune-related |
FCGR3A-HU |
NM-HU-2000073 |
Fcgr4 |
Immunotherapy,drug screening |
Fcgr4-KO |
NM-KO-200196 |
Fcgr4 |
Therapeutic antibody target |
Fcgrt-KO |
NM-KO-205018 |
Fcgrt |
|
FCGRT-HU(M-NSG) |
NM-NSG-020 |
Fcgrt |
Immunotherapy,cancer research,drug screening |
FCGRT-HU&Alb-KO(NOD-SCID) |
NM-KO-200639 |
Fcgrt |
Antigen binding and β-2-microglobulin binding related research,Used to evaluate the pharmacokinetics of Alb modified drugs |
Fcgrt-CKO |
NM-CKO-200094 |
Fcgrt |
Antigen binding and β-2-microglobulin binding related research |
FCGRT-HU(MHCII/B2M-KO) |
NM-NSG-018 |
Fcgrt |
Antibody drug metabolism; drug screening |
FCGRT-HU |
NM-HU-2000032 |
Fcgrt |
Immunotherapy,drug screening |
FCGRT-HU(NOD-scid) |
NM-HU-200006 |
Fcgrt |
Immunotherapy,cancer research,drug screening |
FcRn-HU |
NM-HU-190070 |
Fcgrt |
Immunotherapy,cancer research,drug screening |
FcRn-HU |
NM-HU-00109 |
Fcgrt |
cancer research,Immunotherapy,drug screening |
R26-(hFcRn) |
NM-KI-00081 |
FCGRT |
cancer research;Immunotherapy,drug screening |
Fcgrt-KO |
NM-KO-00133 |
Fcgrt |
Immunotherapy,drug screening |
Fcmr-KO |
NM-KO-200197 |
Fcmr |
Therapeutic antibody target |
Fcna-KO |
NM-KO-201569 |
Fcna |
|
Fcnb-KO |
NM-KO-201570 |
Fcnb |
|
Fcrl1-KO |
NM-KO-200198 |
Fcrl1 |
Therapeutic antibody target |
Fcrla-KO |
NM-KO-201571 |
Fcrla |
|
Fcrlb-KO |
NM-KO-201572 |
Fcrlb |
|
Fcrls-KO |
NM-KO-201573 |
Fcrls |
|
Fem1a-KO |
NM-KO-200858 |
Fem1a |
|
Fem1b-KO |
NM-KO-191164 |
Fem1b |
mediating apoptosis |
R26-Fen1 |
NM-KI-00126 |
Fen1 |
|
Fermt1-KO |
NM-KO-201275 |
Fermt1 |
|
Fga-KO |
NM-KO-202055 |
Fga |
|
Fgb-KO |
NM-KO-200199 |
Fgb |
Therapeutic antibody target |
Fgd4-KO |
NM-KO-200960 |
Fgd4 |
|
Fgd5-(mNeonGreen-2A-CreERT2-polyA) |
NM-KI-200165 |
Fgd5 |
Cre recombinase tool |
Fgf1-KO |
NM-KO-200200 |
Fgf1 |
Therapeutic antibody target |
Fgf12-CKO |
NM-CKO-200302 |
Fgf12 |
|
Fgf12-KO |
NM-KO-190958 |
Fgf12 |
Fibroblast growth factor, VSMC lineage differentiation |
Fgf14-KO |
NM-KO-200961 |
Fgf14 |
|
Fgf2-CKO |
NM-CKO-200066 |
Fgf2 |
FGFR1 mutant receptor activation and microRNA correlation in cardiomyocyte hypertrophy |
Fgf2-KO |
NM-KO-200201 |
Fgf2 |
Therapeutic antibody target |
Fgf21-CKO |
NM-CKO-200176 |
Fgf21 |
Research on lipoprotein metabolism and respiratory electron transport |
Fgf21-KO |
NM-KO-190275 |
Fgf21 |
Immune-related |
Fgf21-CKO |
NM-CKO-00136 |
Fgf21 |
|
Fgf23-CKO |
NM-CKO-200095 |
Fgf23 |
Study on the correlation between FGFR1 mutant receptor activation and RET signaling |
Fgf23-(R176Q) |
NM-KI-200248 |
Fgf23 |
Hypophosphatemic rickets |
Fgf4-KO |
NM-KO-190701 |
Fgf4 |
Cancer-related genes |
Fgf7-KO |
NM-KO-200202 |
Fgf7 |
Therapeutic antibody target |
R26-(CAG-LSL-FGFR2(S320C)-IRES-Luciferase-2A-EGFP) |
NM-KI-190079 |
FGFR2 |
cancer research |
R26-(CAG-LSL-FGFR2(K659N)-IRES-Luciferase-2A-EGFP) |
NM-KI-190078 |
FGFR2 |
cancer research |
R26-(CAG-LSL-FGFR2(W290C)-IRES-Luciferase-2A-EGFP) |
NM-KI-190080 |
FGFR2 |
cancer research |
R26-(CAG-LSL-FGFR3(K562E)-IRES-Luciferase-2A-EGFP) |
NM-KI-190081 |
FGFR3 |
cancer research |
R26-(CAG-LSL-FGFR3(S249C)-IRES-Luciferase-2A-EGFP) |
NM-KI-190082 |
FGFR3 |
cancer research |
R26-(CAG-LSL-FGFR3-IRES-Luciferase-2A-EGFP) |
NM-KI-190083 |
FGFR3 |
cancer research |
Fgfr4-KO |
NM-KO-200203 |
Fgfr4 |
Therapeutic antibody target |
Fgfrl1-KO |
NM-KO-201276 |
Fgfrl1 |
|
Fgg-KO |
NM-KO-201102 |
Fgg |
|
Fgl2-KO |
NM-KO-202056 |
Fgl2 |
|
Fgr-KO |
NM-KO-201574 |
Fgr |
|
Fhit-KO |
NM-KO-190624 |
Fhit |
The protein encoded by this gene is a P1-P3-bis(5'-adenosyl) triphosphate hydrolase involved in purine metabolism. In fact, aberrant transcripts from this gene have been found in about half of all esophageal, stomach, and colon carcinomas. The encoded protein is also a tumor suppressor, as loss of its activity results in replication stress and DNA damage. |
Fibin-KO |
NM-KO-205648 |
Fibin |
secreted protein |
Fjx1-KO |
NM-KO-190959 |
Fjx1 |
Nervous system, hippocampal neuron dendritic complexity |
Fkbp10-CKO |
NM-CKO-210075 |
Fkbp10 |
|
Fkbp4-KO |
NM-KO-201155 |
Fkbp4 |
|
Fkbp5-KO |
NM-KO-190276 |
Fkbp5 |
Immune-related |
Fkbp6-KO |
NM-KO-201156 |
Fkbp6 |
|
Fkbp8-KO |
NM-KO-201277 |
Fkbp8 |
|
Flii-KO |
NM-KO-200962 |
Flii |
|
Flna-KO |
NM-KO-200204 |
Flna |
Therapeutic antibody target |
Flnb-KO |
NM-KO-201575 |
Flnb |
|
Flt3-DreERT2 |
NM-KI-190115 |
Flt3 |
Tool Mice |
Flt3-KO |
NM-KO-190082 |
Flt3 |
Immune-related |
Flvcr1-KO |
NM-KO-205011 |
Flvcr1 |
|
Flvcr1-CKO |
NM-CKO-200054 |
Flvcr1 |
Diseases associated with FLVCR1 include Posterior Column Ataxia With Retinitis Pigmentosa and Posterior Column Ataxia. |
Fmo3-KO |
NM-KO-200734 |
Fmo3 |
|
Fmod-KO |
NM-KO-190277 |
Fmod |
Immune-related |
Fmr1-CKO |
NM-CKO-210080 |
Fmr1 |
|
Fn1-CKO |
NM-CKO-205170 |
Fn1 |
|
Fn1-KO |
NM-KO-200720 |
Fn1 |
|
Fndc1-KO |
NM-KO-200205 |
Fndc1 |
Therapeutic antibody target |
Fndc3b-CKO |
NM-CKO-200307 |
Fndc3b |
|
Fndc5-KO |
NM-KO-190278 |
Fndc5 |
Immune-related |
Fndc7-KO |
NM-KO-205663 |
Fndc7 |
secreted protein |
Fntb-KO |
NM-KO-202057 |
Fntb |
|
PSMA-HU |
NM-HU-200240 |
Folh1 |
|
Folh1-KO |
NM-KO-200206 |
Folh1 |
Therapeutic antibody target |
Fos-(CreERT2) |
NM-KI-200110 |
Fos |
Cre recombinase tool |
Fos-(2A-tdTomato) |
NM-KI-190048 |
Fos |
fluorescent reporter mice |
Fos-(2A-Venus-luci) |
NM-KI-190049 |
Fos |
fluorescent reporter mice |
Fos-KO |
NM-KO-190083 |
Fos |
Immune-related |
Fos-(Venus-Luci) |
NM-KI-18044 |
Fos |
|
Foxd1-(EGFP-iCre) |
NM-KI-200212 |
Foxd1 |
Cre tool mice |
Foxe1-KO |
NM-KO-201278 |
Foxe1 |
|
Foxg1-(Cre) |
NM-KI-200156 |
Foxg1 |
Cre recombinase tool |
Foxh1-KO |
NM-KO-202058 |
Foxh1 |
|
Foxi1-KO |
NM-KO-201279 |
Foxi1 |
|
Foxj1-(GFP-CreERT2) |
NM-KI-200133 |
Foxj1 |
Cre recombinase tool |
Foxj3-KO |
NM-KO-201576 |
Foxj3 |
|
Foxk2-KO |
NM-KO-200796 |
Foxk2 |
|
Foxl1-CreERT2 |
NM-KI-00135 |
Foxl1 |
|
Foxn1-KO |
NM-KO-205001 |
Foxn1 |
|
Foxn1-KO |
NM-KO-200735 |
Foxn1 |
|
Foxn1-(IRES-iCre) |
NM-KI-200106 |
Foxn1 |
Cre recombinase tool |
Foxn1-KO(M-NSG) |
NM-KO-190422 |
Foxn1 |
Immune-related,immunodeficiency,immune system,transplantation research |
Foxn1-KO |
NM-KO-00052 |
Foxn1 |
immune system |
Foxo1-KO |
NM-KO-205036 |
Foxo1 |
|
Foxo1-CKO |
NM-CKO-200177 |
Foxo1 |
Related research on downstream signal events of B cell receptor (BCR) and ERK signaling |
Foxo3-KO |
NM-KO-190084 |
Foxo3 |
Immune-related |
Foxo6-KO |
NM-KO-201577 |
Foxo6 |
|
Foxp1-CKO |
NM-CKO-200168 |
Foxp1 |
Transcriptional regulation of pluripotent stem cells and Wnt/Hedgehog/Notch related research |
Foxp2-HU |
NM-HU-210002 |
Foxp2 |
inmmue therapy;drug screening |
Foxp3-(DreER) |
NM-KI-200198 |
Foxp3 |
Dre tool mice |
Foxp3-(DTR-2A-tdTomato) |
NM-KI-200213 |
Foxp3 |
DTR tool mice |
Foxp3-(IRES-Luci-2A-tdTomato) |
NM-KI-200065 |
Foxp3 |
Treg cell reporter |
Foxp3-(IRES-tdTomato-2A-CreERT2) |
NM-KI-190120 |
Foxp3 |
Cre tool mouse |
Foxp3-(tdTomato-2A-iCre) |
NM-KI-190119 |
Foxp3 |
Tool Mice |
Foxp3-(IRES-DTREGFP) |
NM-KI-190046 |
Foxp3 |
DTR mouse |
Foxp3-(V5-Avi tag-IRES-luci-2A-tdTomato) |
NM-KI-18034 |
Foxp3 |
gene tracing |
Frat1-KO |
NM-KO-190676 |
Frat1 |
Cancer-related genes |
Frem1-KO |
NM-KO-200963 |
Frem1 |
|
Frem2-CKO |
NM-CKO-200294 |
Frem2 |
|
Frem3-KO |
NM-KO-205666 |
Frem3 |
secreted protein |
Frrs1l-KO |
NM-KO-201578 |
Frrs1l |
|
Frzb-KO |
NM-KO-190697 |
Frzb |
Female-specific osteoarthritis (OA) related |
Fscn1-CKO |
NM-CKO-210023 |
Fscn1 |
|
Fscn2-KO |
NM-KO-200964 |
Fscn2 |
|
Fshb-KO |
NM-KO-200207 |
Fshb |
Therapeutic antibody target |
Fshr-KO |
NM-KO-200208 |
Fshr |
Therapeutic antibody target |
Fst-KO |
NM-KO-190279 |
Fst |
Immune-related |
Fstl3-KO |
NM-KO-200209 |
Fstl3 |
Therapeutic antibody target |
Fstl5-KO |
NM-KO-205571 |
Fstl5 |
secreted protein |
Ftcd-KO |
NM-KO-201579 |
Ftcd |
|
Fth1-CKO |
NM-CKO-210019 |
Fth1 |
|
Ftl1-KO |
NM-KO-202059 |
Ftl1 |
|
Fto-CKO |
NM-CKO-190005 |
Fto |
Epigenetic,obesity risk, and type 2 diabetes research |
R26-(CAG-LSL-3xFLAG-Fto-IRES-EGFP) |
NM-KI-190055 |
Fto |
mRNA methylation,obesity risk,and type 2 diabetes research |
Fubp1-CKO |
NM-CKO-210042 |
Fubp1 |
|
Fuca1-KO |
NM-KO-200965 |
Fuca1 |
|
Fut2-KO |
NM-KO-201580 |
Fut2 |
|
Fut4-KO |
NM-KO-200210 |
Fut4 |
Therapeutic antibody target |
Fxyd5-KO |
NM-KO-200841 |
Fxyd5 |
|
Fzd1-KO |
NM-KO-190677 |
Fzd1 |
|
Fzd10-KO |
NM-KO-200211 |
Fzd10 |
Therapeutic antibody target |
Fzd4-KO |
NM-KO-190678 |
Fzd4 |
positive regulator of the Wingless type MMTV integration site signaling pathway |
Fzd5-CKO |
NM-CKO-200178 |
Fzd5 |
Research on ERK signal and Wnt signal |
Fzd6-KO |
NM-KO-190679 |
Fzd6 |
Cancer-related genes |
Fzd7-KO |
NM-KO-190680 |
Fzd7 |
Cancer-related genes |
Fzd8-KO |
NM-KO-190681 |
Fzd8 |
Cancer-related genes |
Fzd9-KO |
NM-KO-190682 |
Fzd9 |
Williams syndrome related |
G6pc-KO |
NM-KO-205040 |
G6pc |
|
G6pc-CKO |
NM-CKO-200053 |
G6pc |
Diseases associated with G6PC include Glycogen Storage Disease Ia and Hypoglycemia. |
G6pc3-KO |
NM-KO-201581 |
G6pc3 |
|
G6pd2-KO |
NM-KO-190800 |
G6pd2 |
|
Gaa-KO |
NM-KO-190085 |
Gaa |
Immune-related |
Gab2-KO |
NM-KO-201582 |
Gab2 |
|
Gabarapl2-KO |
NM-KO-201583 |
Gabarapl2 |
|
Gabbr2-KO |
NM-KO-190960 |
Gabbr2 |
Nervous system, thermal or mechanical stimulation of epilepsy, pain, anxiety and depression |
Gabra1-KO |
NM-KO-190570 |
Gabra1 |
Epilepsy research related |
Gabra3-KO |
NM-KO-200212 |
Gabra3 |
Therapeutic antibody target |
Gabra4-KO |
NM-KO-190572 |
Gabra4 |
Autism research related |
Gabra5-KO |
NM-KO-190573 |
Gabra5 |
|
Gabra6-KO |
NM-KO-190574 |
Gabra6 |
|
Gabrb1-KO |
NM-KO-190575 |
Gabrb1 |
Related to schizophrenia research |
Gabrb3-KO |
NM-KO-201280 |
Gabrb3 |
|
Gabrd-KO |
NM-KO-200604 |
Gabrd |
Diseases associated with GABRD include Epilepsy, Idiopathic Generalized 10 and Chromosome 1P36 Deletion Syndrome. |
Gabre-KO |
NM-KO-190576 |
Gabre |
This gene encodes the gamma-aminobutyric acid (GABA) A receptor which is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. |
Gabrg2-KO |
NM-KO-190577 |
Gabrg2 |
This gene encodes a gamma-aminobutyric acid (GABA) receptor. GABA is the major inhibitory neurotransmitter in the mammlian brain, where it acts at GABA-A receptors, which are ligand-gated chloride channels. Mutations in this gene have been associated with epilepsy and febrile seizures. |
Gabrg3-KO |
NM-KO-190578 |
Gabrg3 |
This gene encodes a gamma-aminobutyric acid (GABA) receptor. GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. |
Gabrq-KO |
NM-KO-190579 |
Gabrq |
This gene encodes the theta subunit of the GABA A receptor,The GABA A receptor is a multisubunit chloride channel that mediates the fastest inhibitory synaptic transmission in the central nervous system. |
Gabrr1-KO |
NM-KO-190580 |
Gabrr1 |
GABRR1 is a member of the rho subunit family. |
Gabrr2-KO |
NM-KO-190581 |
Gabrr2 |
The protein encoded by this gene is a member of the rho subunit family and is a component of the GABA type A receptor complex. This gene exists on chromosome 6q next to the gene encoding the rho 1 subunit of the GABA type A receptor, in a region thought to be associated with susceptibility for psychiatric disorders and epilepsy. Polymorphisms in this gene may also be associated with alcohol dependence, and general cognitive ability. |
Gad2-(IRES-iCre) |
NM-KI-200078 |
Gad2 |
Cre recombinase tool,GAD2 positive neurons. |
Gad2-KO |
NM-KO-200213 |
Gad2 |
Therapeutic antibody target |
Gadd45a-KO |
NM-KO-200590 |
Gadd45a |
Cancer research |
Gadd45b-KO |
NM-KO-190801 |
Gadd45b |
NF-KB pathway |
Gadd45g-KO |
NM-KO-201584 |
Gadd45g |
|
Gal-KO |
NM-KO-190086 |
Gal |
Immune-related |
Galk1-KO |
NM-KO-200214 |
Galk1 |
Therapeutic antibody target |
Galns-KO |
NM-KO-200966 |
Galns |
|
Galnt1-KO |
NM-KO-201281 |
Galnt1 |
|
Galnt18-KO |
NM-KO-201585 |
Galnt18 |
|
Galnt3-KO |
NM-KO-201586 |
Galnt3 |
|
Galnt5-KO |
NM-KO-191141 |
Galnt5 |
|
Galp-KO |
NM-KO-200842 |
Galp |
|
Galr1-KO |
NM-KO-190637 |
Galr1 |
nervous system |
Galt-KO |
NM-KO-200600 |
Galt |
Galactosemia research |
Gamt-KO |
NM-KO-201157 |
Gamt |
|
Gan-KO |
NM-KO-200967 |
Gan |
|
Ganab-KO |
NM-KO-190280 |
Ganab |
Immune-related |
GAPDH-(IRES-mTagBFP) |